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A B S T R A C T
Background
Pressure ulcers, also known as pressure injuries and bed sores, are localised areas of injury to the skin or underlying tissues, or both.
Dressings made from a variety of materials, including foam, are used to treat pressure ulcers. An evidence-based overview of dressings
for pressure ulcers is needed to enable informed decision-making on dressing use. This review is part of a suite of Cochrane Reviews
investigating the use of dressings in the treatment of pressure ulcers. Each review will focus on a particular dressing type.
Objectives
To assess the clinical and cost effectiveness of foam wound dressings for healing pressure ulcers in people with an existing pressure ulcer
in any care setting.
Search methods
In February 2017 we searched: the Cochrane Wounds Specialised Register; the Cochrane Central Register of Controlled Trials (CEN-
TRAL); Ovid MEDLINE (including In-Process & Other Non-Indexed Citations); Ovid Embase; EBSCO CINAHL Plus and the
NHS Economic Evaluation Database (NHS EED). We also searched clinical trials registries for ongoing and unpublished studies, and
scanned reference lists of relevant included studies as well as reviews, meta-analyses and health technology reports to identify additional
studies. There were no restrictions with respect to language, date of publication or study setting.
Selection criteria
Published or unpublished randomised controlled trials (RCTs) and cluster-RCTs, that compared the clinical and cost effectiveness of
foam wound dressings for healing pressure ulcers (Category/Stage II or above).
Data collection and analysis
Two review authors independently performed study selection, risk of bias and data extraction. A third reviewer resolved discrepancies
between the review authors.
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Main results
We included nine trials with a total of 483 participants, all of whom were adults (59 years or older) with an existing pressure ulcer
Category/Stage II or above. All trials had two arms, which compared foam dressings with other dressings for treating pressure ulcers.
The certainty of evidence ranged from low to very low due to various combinations of selection, performance, attrition, detection and
reporting bias, and imprecision due to small sample sizes and wide confidence intervals. We had very little confidence in the estimate
of effect of included studies. Where a foam dressing was compared with another foam dressing, we established that the true effect was
likely to be substantially less than the study’s estimated effect.
We present data for four comparisons.
One trial compared a silicone foam dressing with another (hydropolymer) foam dressing (38 participants), with an eight-week (short-
term) follow-up. It was uncertain whether alternate types of foam dressing affected the incidence of healed pressure ulcers (RR 0.89,
95% CI 0.45 to 1.75) or adverse events (RR 0.37, 95% CI 0.04 to 3.25), as the certainty of evidence was very low, downgraded for
serious limitations in study design and very serious imprecision.
Four trials with a median sample size of 20 participants (230 participants), compared foam dressings with hydrocolloid dressings
for eight weeks or less (short-term). It was uncertain whether foam dressings affected the probability of healing in comparison to
hydrocolloid dressings over a short follow-up period in three trials (RR 0.85, 95% CI 0.54 to 1.34), very low-certainty evidence,
downgraded for very serious study limitations and serious imprecision. It was uncertain if there was a difference in risk of adverse
events between groups (RR 0.88, 95% CI 0.37 to 2.11), very low-certainty evidence, downgraded for serious study limitations and
very serious imprecision. Reduction in ulcer size, patient satisfaction/acceptability, pain and cost effectiveness data were also reported
but we assessed the evidence as being of very low certainty.
One trial (34 participants), compared foam and hydrogel dressings over an eight-week (short-term) follow-up. It was uncertain if the
foam dressing affected the probability of healing (RR 1.00, 95% CI 0.78 to 1.28), time to complete healing (MD 5.67 days 95% CI
-4.03 to 15.37), adverse events (RR 0.33, 95% CI 0.01 to 7.65) or reduction in ulcer size (MD 0.30 cm2 per day, 95% CI -0.15 to
0.75), as the certainty of the evidence was very low, downgraded for serious study limitations and very serious imprecision.
The remaining three trials (181 participants) compared foam with basic wound contact dressings. Follow-up times ranged from short-
term (8 weeks or less) to medium-term (8 to 24 weeks). It was uncertain whether foam dressings affected the probability of healing
compared with basic wound contact dressings, in the short term (RR 1.33, 95% CI 0.62 to 2.88) or medium term (RR 1.17, 95%
CI 0.79 to 1.72), or affected time to complete healing in the medium term (MD -35.80 days, 95% CI -56.77 to -14.83), or adverse
events in the medium term (RR 0.58, 95% CI 0.33 to 1.05). This was due to the very low-certainty evidence, downgraded for serious
to very serious study limitations and imprecision. Reduction in ulcer size, patient satisfaction/acceptability, pain and cost effectiveness
data were also reported but again, we assessed the evidence as being of very low certainty.
None of the included trials reported quality of life or pressure ulcer recurrence.
Authors’ conclusions
It is uncertain whether foam dressings are more clinically effective, more acceptable to users, or more cost effective compared to
alternative dressings in treating pressure ulcers. It was difficult to make accurate comparisons between foam dressings and other dressings
due to the lack of data on reduction of wound size, complete wound healing, treatment costs, or insufficient time-frames. Quality
of life and patient (or carer) acceptability/satisfaction associated with foam dressings were not systematically measured in any of the
included studies. We assessed the certainty of the evidence in the included trials as low to very low. Clinicians need to carefully consider
the lack of robust evidence in relation to the clinical and cost-effectiveness of foam dressings for treating pressure ulcers when making
treatment decisions, particularly when considering the wound management properties that may be offered by each dressing type and
the care context.
P L A I N L A N G U A G E S U M M A R Y
Foam dressings for treating pressure ulcers
What is the aim of this review?
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The aim of this review was to find out whether foam dressings (designed to absorb fluid from wounds whilst keeping them moist) have
any advantages or disadvantages in healing pressure ulcers compared with other dressings (such as silicone foam dressings, hydrocolloid,
hydrogel or basic wound dressings). Researchers from Cochrane collected and analysed all relevant studies (randomised controlled
trials) to answer this question and found nine relevant studies.
Key messages
There is no clear evidence from any of the studies included in this review that foam dressings are more effective at healing pressure
ulcers than other types of dressings; or that foam dressings are more cost effective than other dressings. This is due in part to the low
quality of the studies, many of which had small numbers of participants and did not provide accurate details of their methods.
What was studied in the review?
Pressure ulcers (pressure injuries or bed sores) are wounds that develop on bony parts of the body such as the heels, hips and lower back.
Sitting or lying in the same position for long periods can cause damage to the skin and underlying tissue. People at risk of developing
pressure ulcers include those with limited physical mobility such as people with spinal cord injuries, older people, or those ill in hospital.
Pressure ulcer treatment is a significant burden to patients, their carer(s) and healthcare systems worldwide. Treatments for pressure
ulcers include dressings, antibiotics and antiseptics, and pressure-relieving mattresses or cushions. There are many wound dressings
available to treat pressure ulcers, which vary in cost and may have differing degrees of effectiveness.
Foamdressings are designed to absorb fluid (exudate) that comes from somepressure ulcerwounds, and tomaintain amoist environment.
We wanted to find out how foam dressings affected pressure ulcer healing and recurrence rates. We also wanted to find out whether
foam dressings had an impact on participants’ quality of life and satisfaction with treatment, and whether there were any side effects
such as infection or pain. We also evaluated the cost of foam dressings compared to other treatments.
What are the main results of the review?
We found nine studies published between 1994 and 2016 involving a total of 483 participants with pressure ulcers at Category/Stage
II or above (open wounds). Seven of the nine trials had more female participants than male. On average people in these studies were
59 years or older. The studies compared foam dressings with other types of dressings, however, there was no clear evidence to indicate
foam dressings were more effective at healing pressure ulcers than other types of dressings, or more cost effective. Evidence regarding
reduction in ulcer size, patient satisfaction and pain is very uncertain. None of the studies reported on participants’ quality of life or
pressure ulcer recurrence. The majority of studies found the dressings evaluated were no better or worse than others on the market.
So, while foam dressings can be safely used for the treatment for pressure ulcers, their effect on wound healing is not supported by
scientific evidence.
Generally, the studies we found did not have many participants and the results were often inconclusive. Overall the evidence that exists
is of very low quality.
How up to date is this review?
We searched for studies that had been published up to February 2017.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Hydropolymer foam dressing compared with silicone foam dressing for treating pressure ulcers
Patient or population: people of any age with an exist ing pressure ulcer of Category/ Stage II or above
Setting: any care sett ing
Intervention: silicone foam dressing
Comparison: hydropolymer foam dressing
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with hydropoly-
mer foam dressing
Risk with silicone foam
dressings
Incidence of healed
pressure ulcers, short-
term follow-up (8
weeks or less)
500 per 1000 445 per 1000
(225 to 875)
RR 0.89
(0.45 to 1.75)
38
(1 RCT)
⊕©©©
very low1
Time to complete heal-
ing
Not est imable Not est imable n/ a n/ a Outcome not measured
or reported for this
comparison
Adverse events, short-
term follow-up (8
weeks or less)
150 per 1000 56 per 1000
(6 to 488)
RR 0.37
(0.04 to 3.25)
38
(1 RCT)
⊕©©©
very low2
Quality of life Not est imable Not est imable n/ a n/ a Outcome not measured
or reported for this
comparison
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: conf idence interval; RR: risk rat io
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GRADE Working Group grades of evidence
High quality: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate quality: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1Majority of evidence at high risk of bias due to lim itat ions in design and implementat ion due to lack of blinding (downgraded
once); very serious imprecision of results due to small sample size and wide conf idence intervals (0.45 to 1.75) (downgraded
twice).
2Majority of evidence at high risk of bias due to lim itat ions in design and implementat ion (downgraded once); very serious
imprecision of results due to low number of events and wide conf idence intervals (0.04 to 3.25) (downgraded twice).
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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B A C K G R O U N D
Description of the condition
Pressure ulcers, also known as pressure injuries, decubitus ulcers
and bed sores, are a localised injury to the skin, underlying tissue,
or both, usually occurring over a bony prominence, as a result
of pressure, or pressure in combination with shear stress from
restrictive bedding - where unaligned body weight is pushing one
part of the body such as bone or muscle in one direction, and
another part of the body, usually skin, in the opposite direction
(NPUAP/EPUAP/PPPIA 2014). The development of a pressure
ulcer is a serious complication resulting in pain, decreased quality
of life and significant expenditure of both time and money for
the healthcare industry (VanGilder 2009). Pressure ulcers are an
internationally recognised patient safety problem, estimated to
affect 2.5 million people annually (House 2011).
The main factors associated with the development of pressure ul-
cers are exposure of the skin to excessive pressure, and a reduced
tolerance of the skin to pressure. Pressure is exerted on the skin,
soft tissue, muscle, and bone by the weight of an individual or a
device applied against the surface of their skin. Tissue tolerance
is the ability of the skin and its supporting structures to toler-
ate the effects of pressure by distributing it (cushioning) and by
the transfer of pressure loads from the skin surface to the skele-
ton (NPUAP/EPUAP/PPPIA 2014). Tissues are capable of with-
standing enormous pressures briefly, but prolonged exposure to
pressure initiates a series of events that lead potentially to necrosis
and ulceration.
Factors that increase pressure on the skin include impairments in
mobility, activity or sensory perception, because the pressure is not
relieved by movement or changes to body position. Internal risk
factors for the development of pressure ulcers include advancing
age, poor nutrition, poor perfusion and oxygenation, whereas, ex-
ternal risk factors include increased moisture, shear and friction.
Shear forces and friction aggravate the effects of pressure upon
tissue and are important components of the mechanism of injury.
A combination of pressure, shear forces, and friction causes mi-
crocirculatory occlusion (blockage), resulting in ischaemia and tis-
sue anoxia (lack of oxygen) and stimulation of inflammatory pro-
cesses, whichmay lead to cell death, ulceration, and tissue necrosis.
Irreversible tissue damage may occur in vulnerable people after as
little as 30 minutes of uninterrupted pressure (Kirman 2008). In
addition, excessive contact of the skin to fluids impairs its barrier
function, causes maceration and an increased risk of the develop-
ment of a pressure ulcer.
A number of systems for describing the degree of tissue damage
exist, but pressure ulcers are generally categorised as Category/
Stage I, II, III, and IV according to the depth of tissue damage;
Category/Stage I pressure ulcers are the least severe and are often
difficult to detect and Category/Stage IV are the most severe with
complete tissue destruction (Moore 2005), as illustrated in Table 1
(NPUAP/EPUAP/PPPIA 2014). The majority of pressure ulcers
occur on the sacrum (base of the spine) or heel, but they also occur
frequently over the elbow, hip - including the ischium, shoulder,
spinous processes on vertebrae, ankle, toe, head or face (Lahmann
2006; Shanin 2008; Vanderwee 2007).
Prevalence of pressure ulcers
The prevalence of pressure ulcers is dependent upon patient fac-
tors and treatment settings (Vanderwee 2007; VanGilder 2009). A
study undertaken in European acute care settings found an overall
prevalence of 18.1% or 10.5% if Category/Stage I pressure ulcers
were excluded with individual countries reporting prevalence rates
between 8.3% and 23% (Vanderwee 2007). A more recent survey
of the USA estimated a per-annum pressure ulcer prevalence of
12% to 13% in acute care settings and 29% to 32% in longer-
term acute care settings (VanGilder 2009). It should be noted that
this survey excluded Category/Stage I pressure ulcers from preva-
lence calculations due to the substantial inaccuracies associated
with their assessment (VanGilder 2009). Within Australia, pres-
sure ulcer point prevalence studies conducted by the Victorian
Government in 136 metropolitan and rural health service sites
between 2003 and 2006 resulted in a decrease in the prevalence of
people with pressure ulcers (categories/stages I to IV) from 26.5%
to 17.6%. However the proportion of people with pressure ulcers
acquired in hospital did not change (67.6% in 2003 versus 67.7%
in 2006 (QSB 2006). These international studies of prevalence
illustrate the extent of the burden of pressure ulcer, however vari-
ability in prevalence in similar settings suggests pressure ulcers are
amenable to intervention, with substantial potential for improve-
ment in patient and financial outcomes.
Economic burden of pressure ulcers
Internationally, there has been substantial investment over recent
decades in monitoring, preventing and treating pressure ulcers in
an attempt to reduce their incidence and associated costs. As a
result there is increasing evidence of the economic burden of pres-
sure ulcers. Graves 2014 applied a probabilistic model to estimate
the direct health cost of pressure ulcers in hospital and residential
care settings in Australia for 2010 to 2011. They reported a mean
number of pressure ulcer cases of 345,768 in public and private
hospitals, at a mean cost of USD 1.64 billion In long-term and
respite residential aged care settings, they reported 10,397 cases of
pressure ulcer at a mean cost of USD 13.9 million for a combined
total of USD 1.65 billion. Another Australian cost-of-illness study
(Nguyen 2015) used a prevalence approach and simulation meth-
ods to estimate the costs of pressure ulcers using 2012 to 2013
public hospital data. Based on a total number of 121,645 reported
pressure ulcers cases, and 524,661 bed days lost, they estimated
the cost as AUD983million per annum, or 1.9% of all public hos-
pital expenditure. Opportunity costs were also estimated adding
AUD 820 million per annum to the overall cost of pressure ulcers
6Foam dressings for treating pressure ulcers (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
of AUD 1.8 billion. In 2011, Dealey 2012 and colleagues used a
bottom-up methodology to estimate the approximate total cost of
pressure ulcers in the UK as GBP 3.36 billion annually with an
expected average cost of healing a Category/Stage III or IV ulcer
of between GBP 9000 and GBP 14,000. In the USA, total costs
for treatment of pressure ulcers reported in 2014 were estimated
at USD 9.1 to USD 11.6 billion annually, with 2.5 million people
affected and approximately 60,000 deaths resulting from pressure
ulcers (AHRQ 2014). The main costs incurred for the treatment
and management of pressure ulcers are due to prolonged hospital-
isation and the extent of nursing care required. Although the in-
dependent effects of a pressure ulcer on length of hospital stay are
likely to vary between studies, authors of a report from the USA
identified that the average length of acute hospital stay for adults
with a pressure ulcer (Category/Stage not identified) was longer
for younger age groups, and ranged from14.1 days for people aged
between 18 and 44 years, 12.4 days for people aged 65 to 84 years
and 10.2 days for people aged 85 years and older (Russo 2003).
In comparison, the average length of stay for all hospitalisations
in 2003 was 4.6 days. In addition to the increased time spent in
hospital, the discomfort and pain experienced, the burden upon
the person with the pressure ulcer - and the cost to the health
services - are compounded by the increased risk of mortality, al-
tered body image and reduced quality of life, together with the
potential cost associated with financial penalties for this largely
preventable condition (VQC 2004), such as those imposed by the
Queensland Government for severe pressure ulcers (Miles 2013).
In spite of the level of investment in prevention and monitoring of
pressure ulcers, many people continue to develop them. This is the
case particularly in acute and long-term care settings where people
may present with a several risk factors such as decreased mobility,
impaired perfusion, poor nutrition, and fluctuating health status
(Dealey 2012). Pressure ulcer treatment strategies are often costly
and complex.
Description of the intervention
Treatment of a pressure ulcer is primarily two-fold and involves the
relief of pressure allied with wound management. Other general
strategies include patient education, painmanagement, optimising
circulation/perfusion, optimising nutrition and the treatment of
clinical infection (NPUAP/EPUAP/PPPIA 2014). Wound man-
agement may involve surgical or chemical debridement (removal
of dead tissue) and dressings to protect the wound and possibly
promote healing. Dressings can be divided into four main cate-
gories, namely, basic wound dressings, advanced wound dressings,
anti-microbial dressings and specialist dressings. Classification of
a dressing depends on its purpose and the key material used in
its composition. Key attributes of a dressing have been described
(BNF 2016), and include: the ability of the dressing to absorb and
contain exudate without leakage or strike-through (saturation);
lack of particulate contaminants left in the wound by the dress-
ing; thermal insulation; permeability to water but not to bacteria;
avoidance of wound trauma on dressing removal; frequency with
which the dressing needs to be changed; provision of pain relief;
and comfort.
Foam dressings, the properties of which are described below, are
the focus of this review. As foam dressings are likely to be evaluated
against one of the many wound dressings available, we have pro-
vided a description of potential comparators, categorised accord-
ing to the British National Formulary structure, and listed by their
generic names and manufacturers (BNF 2016). Dressing names,
manufactures and distributors may vary between countries.
Basic wound contact dressings
• Low-adherence dressings and wound contact materials:
these usually consist of cotton pads that are placed directly in
contact with the wound and are designed to prevent minimal
adherence to the wound bed and so present less risk of trauma to
the wound as it is removed for subsequent and ongoing
treatment. The addition of paraffin and similar substances is to
prevent the dressing from sticking to the wound.
• Absorbent dressings: these dressings are applied directly to
the wound and maybe used as secondary absorbent layers in the
management of heavily exuding wounds.
Advanced wound dressings
• Foam dressings: these dressings normally contain
hydrophilic (water absorbant) polyurethane foam designed to
absorb wound exudate while maintaining a moist wound surface.
There are a variety of versions including those with additional
absorbent materials such as viscose and acrylate fibres, or
particles of superabsorbent polyacrylate, while others are
silicone-coated for atraumatic removal.
• Alginate dressings: these dressings are highly absorbent
fabrics/yarns that come in the form of calcium-alginate or
calcium-sodium-alginate and can be combined with collagen.
The alginate forms a gel when in contact with the wound surface
which can be lifted off at dressing removal, or rinsed away with
sterile saline. Bonding to a secondary viscose pad increases
absorbency.
• Hydrogel dressings: these dressings consist of cross-linked
insoluble polymers consisting of starch or
carboxymethylcellulose, and up to 96% water. They are designed
to absorb wound exudate or to rehydrate a wound depending on
the wound moisture levels. They are supplied in either flat
sheets, amorphous hydrogel or as beads.
• Hydrocolloid dressings: these occlusive dressings are
usually composed of a hydrocolloid matrix bonded to vapour-
permeable film or foam backing. This matrix forms a gel that
provides a moist environment when in contact with the wound
surface. Fibrous alternatives resembling alginates have also been
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developed. These are more absorbant than standard hydrocolloid
dressings but are not occlusive.
• Films, permeable film and membrane dressings: these
dressings are permeable to water vapour and oxygen, but not to
water or micro-organisms.
• Capillary-action dressings: these dressings consist of an
absorbent core of hydrophilic fibres held between two low-
adherent contact layers.
• Odour-absorbent dressings: these dressings contain
charcoal and are used to absorb wound odour, often in
conjunction with a secondary dressing to improve absorbency.
Antimicrobial dressings
• Honey-impregnated dressings: these dressings contain
medical-grade honey which is thought to have antimicrobial and
anti-inflammatory properties and can be used for acute or
chronic wounds.
• Iodine-impregnated dressings: these dressings release free
iodine, which is thought to act as a wound antiseptic when
exposed to wound exudate.
• Silver-impregnated dressings: these dressings are used to
treat infected wounds, as silver ions are thought to have
antimicrobial properties. Silver versions of most dressing types
are available (e.g. silver foam, silver hydrocolloid).
• Other antimicrobial dressings: these dressings are
composed of a gauze or low adherent dressing impregnated with
an ointment thought to have antimicrobial properties.
Specialist dressings
• Protease-modulating matrix dressings: these dressings are
designed to alter the activity of proteolytic enzymes in chronic
wounds and are thought to promote natural debridement.
The diversity of dressings available to clinicians (including varia-
tion within each type listed above) makes evidence-based decision
making difficult when determining the optimum treatment regi-
men for a particular person (Gillespie 2012). Some dressings are
formulated with an ’active’ ingredient such as silver that is pro-
moted as a dressing treatment option to reduce infection and pos-
sibly to promote healing. With increasingly sophisticated technol-
ogy being applied to wound care, practitioners need to know how
effective these, often expensive, dressings are compared with more
traditional and usually less costly dressings.However, far frompro-
viding critical evaluation of dressing types for clinical use, studies
have shown wide variation in practice and wound care knowledge
(Reddy 2008;Maylor 1997; Pieper 1995), and the number of eco-
nomic evaluations of wound dressings available is limited (NICE
2017).
How the intervention might work
The principle of moist wound healing directs contemporary
wound care. This is optimised through the application of occlu-
sive or semi-occlusive dressings and preparation of the wound bed
(NPUAP/EPUAP/PPPIA 2014). Animal experiments performed
50 years ago suggested that acute wounds healed more quickly
when their surface was kept moist, rather than being left to dry
and scab (Winter 1962; Winter 1963a; Winter 1963b). A moist
environment is thought to provide optimal conditions for the cells
involved in the healing process, as well as allowing autolytic de-
bridement (removal of dead tissue by natural processes), which
is thought to be an important component of the healing path-
way (Cardinal 2009). The desire to maintain a moist wound en-
vironment is an important factor in the choice of wound dressing.
Wound dressings vary in their level of absorbency so that a dry
wound may be treated with an occlusive dressing to maintain a
moist environment to promote healing. Alternatively a wet wound
may be treated with a more absorbant dressing (such as a foam
dressing) to draw excess moisture away from the area of injury and
avoid skin damage.
Why it is important to do this review
Pressure ulcers are a relatively common yet complex type of wound
that are a significant source of suffering for patients and their loved
ones and an economic burden to healthcare systems (Reddy 2008).
They are an internationally recognised patient safety problem and
serve as a clinical indicator for the standard of care provided. As
a result, significant investment has been made in strategies aimed
at pressure ulcer prevention. However, pressure ulcers remain a
prevalent condition in many care settings. Dressings are widely
used as a treatment strategy for pressure ulcers, and understand-
ing the existing evidence base and potential uncertainty around
clinical efficacy and cost-effectiveness of different dressing types is
important for effective decision making.
Internationally accepted guidelines recommend that dressings that
keep the woundmoist should be used, based upon level C evidence
that is “supported by indirect evidence (e.g., studies in healthy hu-
mans, humans with other types of chronic wounds, animal mod-
els) and/or expert opinion” (NPUAP/EPUAP/PPPIA 2014). The
same guidelines suggest that foam dressings be used to treat pres-
sure ulcers in various scenarios, mainly for the treatment of ex-
uding Category/Stage II and shallow Category/Stage III pressure
ulcers, however these recommendations are based on limited evi-
dence (NPUAP/EPUAP/PPPIA 2014).
Two notable systematic reviews of treatments for pressure ulcers
have included trials of dressings (Reddy 2008; Smith 2013). Reddy
2008 reported that “No single dressing was consistently superior
to other dressings in the trials of pressure ulcers we examined” (p.
2659). This finding was consistent with earlier systematic reviews
by Chaby 2007 and Hamilton 2008, which found no evidence
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that one particular dressing type was more clinically effective or
cost effective than another. More recently a review by Smith 2013
included dressing interventions but did not specifically identify
foam dressings. We conclude that up-to-date and transparent in-
formation on evidence for the use of dressings to treat pressure
ulcers and cost effectiveness is required.
This review is part of a suite of Cochrane Reviews investigating the
use of dressings in the treatment of pressure ulcers. Each reviewwill
focus on a particular dressing type and then be summarised in an
overview of reviews that will draw together all existing Cochrane
Review evidence regarding the use of dressings to treat pressure
ulcers.
O B J E C T I V E S
To assess the clinical and cost effectiveness of foam wound dress-
ings for healing pressure ulcers in people with an existing pressure
ulcer in any care setting.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included all randomised controlled trials (RCTs) and cluster-
RCTs irrespective of publication status or language. We excluded
non-randomised, clinical controlled trials and cross-over trials.
The critical review of health economic evidence included, where
possible, comparative full and partial economic evaluations con-
ducted within the framework of eligible RCTs and cluster-RCTs
(i.e. cost-effectiveness analyses, cost-utility analyses, cost-benefit
analyses and cost analyses that included a dressing intervention
and a relevant comparator), as well as RCTs reportingmore limited
information, such as estimates of resource use or costs associated
with dressings and a comparator. We only considered health eco-
nomics studies conducted alongside effectiveness studies that were
included in the clinical effectiveness component of the review.
Types of participants
We included studies that recruited people of any age (no upper age
limit was set) with a diagnosis of pressure ulcer of Category/Stage
II or above in any care setting using the NPUAP/EPUAP/PPPIA
2014. We also used alternative pressure ulcer classification sys-
tems, such as the Stirling (Reid 1994) and Torrence classification
systems (Harker 2000), as well as earlier versions published by the
NPUAP (NPUAP 1989), on the condition that the definitions of
these alternative and previous versions closely matched the con-
temporary International NPUAP/EPUAP/PPPIA Pressure Ulcer
Classification System Criteria (NPUAP/EPUAP/PPPIA 2014).
See Table 2 ’Comparison of pressure ulcer classification systems’.
We excluded studies involving participants with Category/Stage
I ulcers because although ’at-risk’ signs and symptoms of poten-
tial pressure ulcer such as non-blanchable redness, pain, hard-
ness or softness, heat or coolness are present, the skin remains
intact (NPUAP/EPUAP/PPPIA 2014). A posteriori uncertainty
about what constituted a Category/Stage I and II pressure ulcer in
alternative pressure ulcer classification systems required changes
to original protocol. These are outlined in Differences between
protocol and review.
Types of interventions
The primary intervention under investigation is the use of any
foamwound dressing for treatingCategory/Stage II pressure ulcers
or above. We included any trial in which the presence or absence
of a foam dressing was the only systematic difference between
treatment groups.We anticipated that comparisons would include
the following:
• different types of foam dressings compared with each other;
• foam dressings compared with other dressings or active
treatments, or both, and;
• foam dressings compared with no dressing treatment.
Types of outcome measures
For clarity we present data for short-term follow-up (8 weeks or
less); medium follow-up (24 weeks or less) and long-term follow-
up (more than 24 weeks). This change is noted in Differences
between protocol and review.
Primary outcomes
• Incidence of healed pressure ulcers (proportion of
participants in whom a pressure ulcer healed)
• Time to complete healing
• Adverse events per participant (such as wound or systematic
infection, or both, or increase in ulcer size and severity)
Secondary outcomes
• Reduction in ulcer size
• Quality of life (measured using any validated tool)
• Patient satisfaction/acceptability measured using any
validated tool
• Pressure ulcer recurrence (Category/Stage II or above)
• Pain (associated with a pressure ulcer or dressing removal,
or both, measured by any validated tool)
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Economic outcomes
• Cost (including but not limited to: costs of dressings; costs
of related nursing or other health practitioner time or
consultations; treatment costs per participant per pressure ulcer;
costs to treat adverse events, infections or complications
associated with the pressure ulcer; duration or costs of hospital
stay for pressure ulcer wound healing, adverse events and
complications; indirect costs to society associated with pressure
ulcer such as lost productivity)
• Utility scores representing health-related quality of life
• Incremental cost per event such as per additional pressure
ulcer healed; incremental cost per life year gained; incremental
cost per quality-adjusted life year (QALY); net health or
monetary benefit)
Search methods for identification of studies
Electronic searches
We searched the following electronic databases to identify reports
of relevant clinical trials and economic studies:
• the Cochrane Wounds Specialised Register (searched 27
February 2017);
• the Cochrane Central Register of Controlled Trials
(CENTRAL; 2017, Issue 1) in the Cochrane Library (searched
27 February 2017);
• Ovid MEDLINE including In-Process & Other Non-
Indexed Citations (1946 to 27 February 2017);
• Ovid Embase (1974 to 27 February 2017);
• EBSCO CINAHL Plus (1937 to 27 February 2017);
• the NHS Economic Evaluation Database (NHS EED) in
the Cochrane Library (searched 27 February 2017).
The search strategies for the Cochrane Wounds Specialised Regis-
ter, CENTRAL, NHS EED, OvidMEDLINE, Ovid Embase and
EBSCO CINAHL Plus can be found in Appendix 1. We com-
bined theOvidMEDLINE searchwith theCochrane Highly Sen-
sitive Search Strategy for identifying randomised trials in MED-
LINE: sensitivity- and precision-maximising version (2008 re-
vision) (Lefebvre 2011). We combined the Embase search with
the Ovid Embase filter developed by the UK Cochrane Centre
(Lefebvre 2011). We combined the CINAHL Plus searches with
the trial filters developed by the Scottish Intercollegiate Guidelines
Network (SIGN 2017). To identify economic studies, we com-
bined Ovid MEDLINE, Ovid Embase, and EBSCO CINAHL
Plus searches with filters developed by the Centre for Reviews and
Dissemination (CRD 2017). There were no restrictions with re-
spect to language, date of publication or study setting.
We also searched the following clinical trials registries:
• ClinicalTrials.gov (searched 3 March 2017);
• World Health Organization (WHO) International
Clinical Trials Registry Platform (searched 3 March 2017);
• EU Clinical Trials Register (searched 3 March 2017).
Search strategies for clinical trials registries can be found in
Appendix 1.
Searching other resources
Searching reference lists of included trials and relevant
reviews
We aimed to identify other potentially eligible trials or ancillary
publications by searching the reference lists of retrieved included
trials, as well as relevant systematic reviews, meta-analyses and
Health Technology Assessment reports.
Contacts
We attempted to contact authors of papers and abstracts that were
identified as having omissions of reported data, to request further
information about their trials. However given that eight of the
nine studies were published nine to 23 years ago, we had limited
success making contact with authors, or where contact was made,
authors were unable to access original data.
Adverse effects
We did not perform a separate search for adverse effects of inter-
ventions used, we considered adverse effects described in included
studies only.
Data collection and analysis
We carried out data collection and analysis using ReviewManager
5 (RevMan 5) (RevMan 2014) according tomethods pre-specified
in a published protocol (Walker 2014).
Selection of studies
Two review authors independently assessed the titles and abstracts
of all citations retrieved by the search for relevance against the in-
clusion criteria. After this initial assessment, we retrieved full-text
versions of all studies considered to be potentially eligible. The
same two authors then independently assessed the full papers for
eligibility and disagreement between review authors was resolved
through discussion and, when required, via input by a third in-
dependent review author (Higgins 2011a). When the eligibility
of a study was unclear, we attempted to contact study authors to
request clarification. We recorded all the reasons for exclusion of
studies we obtained as full copies, and completed a PRISMA flow
chart to summarise this process (Liberati 2009).We also attempted
to obtain all relevant publications when studies had reportedmore
than once.
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Data extraction and management
We extracted and summarised details from eligible studies using a
pre-designed data extraction sheet. Two review authors extracted
data independently and then performed a cross-check for accu-
racy and agreement. Any disagreements were resolved though dis-
cussion and arbitration by a third review author when necessary.
Where studies were reported multiple times, we obtained all pub-
lications to ensure that we extracted the maximum amount of rel-
evant data and included the study once in the review. When we
included a study with more than two intervention arms, we ex-
tracted data only from the intervention and control groups as per
the eligibility criteria. If there were any data missing from the pa-
pers, we attempted to contact study authors to retrieve themissing
information.
Where possible, we extracted the following data from those trial
arms relevant to the review:
• country of origin;
• type/Category/Stage of pressure ulcer;
• location of pressure ulcer;
• unit of investigation (per participant) - single injury versus
multiple injuries per participant;
• care setting;
• eligibility criteria and key baseline participant data;
• number of participants randomised to each trial arm;
• details of the dressing treatment/regimen received by each
group;
• details of any co-interventions;
• primary and secondary outcome(s) with definitions;
• outcome data for primary and secondary outcomes (by
group);
• duration of follow-up;
• number of withdrawals (by group); and,
• source of funding.
We extracted the following data from economic studies relevant
to the review:
• estimates of specific items of resource use per participant;
• estimates of unit costs (extracted separately to resource use);
• price year and currency;
• decision making jurisdiction;
• analytic perspective;
• both a point estimate and a measure of uncertainty (e.g.
standard error or confidence interval) for measures of incremental
resource use, costs and cost effectiveness, if reported; and
• details of any sensitivity analyses undertaken, and any
information regarding the impact of varying assumptions on the
magnitude and direction of results.
Assessment of risk of bias in included studies
Two review authors independently assessed included studies for
risk of bias using the Cochrane ’Risk of bias’ assessment tool
(Higgins 2011b). The tool addresses six specific domains (re-
fer to Appendix 2), namely sequence generation, allocation con-
cealment, blinding, incomplete outcome data, selective outcome
reporting and other issues that may potentially bias the study
(Higgins 2011b). We linked Cochrane ’Risk of bias’ ratings to the
GRADE assessment using an adaptation by Guyatt 2011 to define
the four ’Risk of bias’ ratings (Westby 2017):
• very high - two or more key domains with a high risk of
bias or a single domain with very high levels of uncertainty (e.g.
very high degree of differential missing data);
• high - high risk of bias for any one domain or we judged the
risk of bias to be ’almost high’ across more than one domain;
• low - low risk of bias for each of the key domains;
• unclear - insufficient information for at least one key
domain (with the other domains being at low risk of bias).
As we only included RCTs and cluster-RCTs in this review, our
GRADE ratings started at ’high’ (according to the GRADE qual-
ity rating system of high, moderate, low, very low). However we
downgraded studies according to five factors: 1) limitations in
the design and implementation suggesting the high likelihood of
bias; 2) indirectness of evidence (indirect population, interven-
tion, control, outcomes); 3) unexplained heterogeneity or incon-
sistency of results; 4) imprecision of results; 5) high probability of
bias (Schünemann 2011a). Explanations for our GRADE assess-
ment decisions are presented in the footnotes to the ’Summary of
findings’ tables.
We completed a ’Risk of bias’ table for each included study, and
conducted a separate assessment for each outcome. We have pre-
sented ’Risk of bias’ assessment using two ’Risk of bias’ summary
figures: one that provides a summary of bias for each item across
all studies and another that provides a cross-tabulation of each trial
for all risk of bias items. For economic evaluations, we used the
Consolidate Health Economic Evaluation Reporting Standards
(CHEERS) checklist to assess the methodological quality of full
and partial economic evaluations (Husereau 2013).
Measures of treatment effect
For dichotomous outcomes, we calculated risk ratio (RR) with
95% confidence intervals (CI). For continuous outcomes, we used
the mean difference (MD) with 95% CIs for trials that used the
same assessment scale.When trials used different assessment scales,
we planned to use the standardised mean difference (SMD) with
95%CIs. Time-to-event data (e.g. time-to-healing) were intended
to be reported as hazard ratio (HR) when possible, in accordance
with the methods described in the Cochrane Handbook for Sys-
tematic Reviews of Interventions (Deeks 2011). If studies reporting
time-to-event data (e.g. time to healing) did not report a hazard
ratio then, when feasible, we planned to estimate this using other
reported outcomes, such as numbers of events via an appropriate
statistical method (Tierney 2007).
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Review of economic evaluations
We planned to present a tabulated analysis of the identified eco-
nomic data in accordance with advice outlined in the CHEERS
checklist (Husereau 2013). However, limited data made it imprac-
tical to do so. Instead we have presented a narrative description of
the economic data.
For any included studies, given the likely lack of direct comparabil-
ity in resource use and cost data between different healthcare con-
texts and settings, we did not intend to pool economic outcomes.
Rather we planned to incorporate a discussion of key drivers and
impact of assumptions on the cost-effectiveness of foam dressings,
scenarios that are likely to lead to the most and least cost-effective
use of foam dressings, as well as guidance on future research that
might be required to assess the economic value of foam dressings
as an intervention for pressure ulcer treatment.
Costs
Weplanned to report resource utilisation and unit costs separately,
along with the currency and price year in each original study. We
would then convert these costs to current values by employing a
web-based conversion tool that applies implicit price deflators for
gross domestic product (GDP) of that currency and then converts
into the currency most frequently observed in the articles reviewed
using GDP Purchasing Power Parities (Shemilt 2011). This would
allow readers of the review to make meaningful comparisons be-
tween costs in studies that may have been conducted in different
countries and at different times. However, given that only three
studies reported costs for different components of pressure ulcer
treatment, across different comparisons, we did not consider it
appropriate to convert costs to a common currency and year.
The main costs were likely to be those associated with the de-
velopment of pressure ulcers and their treatment (e.g. dressings),
nursing time for dressing changes, specialist and other practitioner
costs as measured by time or number of visits, potential cost-sav-
ings from a reduced length of stay in hospital, and costs stemming
from differing rates of adverse events and complications (includ-
ing procedures initiated due to the failure of wounds to heal, such
as amputation). We planned to identify the key cost drivers from
the studies included to enable users of the review to gain a clear
understanding of the nature of resource use associated with foam
dressing for pressure ulcer treatment.
Health state utility scores
We planned to examine information on the change in health-
related quality of life reported by the included trials via utilities
measured by a multi-attribute utility instrument (MAUI) or other
approaches (such as the time trade-off, standard gamble).
Unit of analysis issues
In most of the studies included in our review, the participant was
the unit of analysis, taking into account the level atwhich randomi-
sation occurred. For parallel-group designs, we analysed a single
measure for each outcome for each person participating, thereby
avoiding ’unit-of-analysis’ errors that can result in a false positive
conclusion that the intervention had an effect (Deeks 2011). For
cluster-RCTs (e.g. where outcomedatawere presented formultiple
ulcers per participant) we had planned to adjust sample size based
on methods described in the Cochrane Handbook for Systematic
Reviews of Interventions (Deeks 2011); that is, where possible, use
an estimate of intra-cluster correlation coefficient (ICC) derived
from the trial, or calculate the design effect using the formula:
DE = 1 (M-1) x ICC (Deeks 2011). However, in the one study
with clustered data, we did not do this due to the small amount
of data, the age of the study and resulting lack of detail about the
data. Instead we matched the number of observations with the
number of ’units’ (i.e. participants) randomised, and reflected the
lack of independence in the study via the risk of bias and GRADE
assessment.
Dealing with missing data
We considered it likely that studies included in our review would
have missing data, which would increase the possibility of bias.
Where there was evidence ofmissing data, we attempted to contact
study authors to request the missing information. In cases where
this approachwas unsuccessful, we assumed thatmissing data were
due to loss of follow-up (missing at random) and analysed the
available information. If we considered that data were not missing
at random, we planned to either impute missing data, acknowl-
edging that these were imputed with uncertainty or to use statisti-
cal models to allow for missing data by making assumptions about
their relationship with the available data (Deeks 2011), or adopt
both process (we did not use these options in the review). We con-
sidered intention-to-treat (ITT) analysis (keeping participants in
the intervention groups to which they were randomised, regard-
less of the intervention they actually received) where some ran-
domised participants were excluded from the analysis. Where we
assessed ITT analysis as inappropriate (in cases of unintended/ad-
verse events), we considered available case analysis (Deeks 2011).
We planned to perform sensitivity analyses to assess how robust
the results were to reasonable changes in the assumptions that we
made. We have addressed the impact of missing data on the find-
ings of the review in the Discussion section.
Assessment of heterogeneity
Based on previous reviews of the literature, there was an expecta-
tion that included studies would have considerable heterogeneity
due to clinical variation (differences in participants, interventions
and outcomes), andmethodological diversity related to design and
risk of bias difference (Deeks 2011), which resulted in statistical
heterogeneity (Higgins 2003). Therefore, we attempted to identify
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potential sources of clinical, methodological and statistical hetero-
geneity prior to meta-analysis. We analysed studies of each inter-
vention and presented data separately. If studies were sufficiently
homogeneous, we pooled data using meta-analysis with RevMan
5 (RevMan 2014). We used the Chi2 test to quantify our assess-
ment of statistical heterogeneity, with significance being set at P
value less than 0.10 and the I2 measure. We did not pool stud-
ies with high returned values - classed as when I2 exceeded 75%
(Deeks 2011).Where there were sufficiently similar studies to con-
sider pooling, we used a fixed-effect model to quantify an estimate
of low to moderate levels of heterogeneity (I2 0% to 50%). We
planned to use a random-effects model in the absence of clinical
heterogeneity and in the presence of statistical heterogeneity (I2
> 50%), However this was not possible due to the high degree of
clinical variation.
Assessment of reporting biases
Reporting biases arise when the dissemination of research find-
ings is influenced by the nature and direction of results (Sterne
2011). Publication bias is one example of a number of possible
’small study effects’, such as a tendency to over-estimate the effect
of interventions in smaller RCTs. We planned to explore reporting
bias using funnel plots. A funnel plot is a simple scatter plot that
enables a visual assessment of intervention effect estimates from
individual RCTs against some measure of each trial’s size or preci-
sion (Sterne 2011). We had planned to present funnel plots if at
least 10 studies were available for the meta-analysis, however this
situation did not arise.
Data synthesis
We described included studies in a structured narrative summary
based upon comparators.
We entered quantitative data into RevMan 5 (RevMan 2014), and
analysed the data using the RevMan 5 analysis software. For di-
chotomous outcomes, we calculated RR plus 95%CI. For contin-
uous outcomes, we intended to calculate SMD andMD plus 95%
CI. For time-to-event outcomes we planned to calculate pooled
HR with 95% CI. The decision to pool data in a meta-analysis
was dependent upon the availability of outcome data and assess-
ment of between-trial heterogeneity. We explored the robustness
of meta-analyses using appropriate meta-analytical models - such
as fixed-effect or random-effects models, based on the level of het-
erogeneity as outlined in the Cochrane Handbook for Systematic
Reviews of Interventions (Deeks 2011).
’Summary of findings’ tables
We have presented the main results of the review in ’Summary of
findings’ tables. These tables present key information concerning
the quality of the evidence, the magnitude of the effects of the
interventions examined, and the sum of the available data for the
main outcomes (Schünemann 2011b). The ’Summary of findings’
tables also include an overall grading of the body of evidence re-
lated to each of the main outcomes using the GRADE approach
(Schünemann 2011a). The GRADE approach defines the quality
of a body of evidence as the extent to which one can be confident
that an estimate of effect or association is close to the quantity of
specific interest. As this review is part of a suite of Cochrane Re-
views investigating the use of a wide range of dressing types for the
treatment of pressure ulcers, reviewed studies here include those
from a select range of advanced wound dressing types. Based on
the characteristics of included studies, the ’Summary of Findings’
tables have been organised according to the following comparisons
with each table comprising results from several individual studies:
• different types of foam dressings compared with each other;
• foam dressings compared with hydrocolloid dressings;
• foam dressings compared with hydrogel dressings;
• foam dressings compared with basic wound contact
dressings.
We have presented data on the following outcomes:
• incidence of healed pressure ulcers (proportion of
participants in whom a pressure ulcer healed);
• time to complete healing;
• adverse events per patient (such as wound or systematic
infection, or both, or increase in ulcer size and severity;
• quality of life.
Subgroup analysis and investigation of heterogeneity
We had planned, if data allowed, to undertake the following sub-
group analysis: type of setting (community, hospital, inpatient,
outpatient) however this was not possible and we have not pre-
sented any subgroup analyses.
Sensitivity analysis
When possible we planned to perform sensitivity analysis to ex-
plore the influence of risk of bias on clinical, methodological and
statistical heterogeneity (Deeks 2011). As a result of this process,
we planned to exclude those studies assessed as having high risk
of bias from meta analysis and consider the effects of those stud-
ies at unclear risk or low risk of bias. We considered studies as
having overall low risk of bias if they had low risk of bias in all
key domains, namely adequate generation of the randomisation
sequence, adequate allocation concealment and blinding of out-
come assessor for the estimates of treatment effect. We did not
conduct this analysis.
R E S U L T S
Description of studies
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See Characteristics of included studies; Characteristics of excluded
studies
Results of the search
The search generated 1352 records (registers were checked on 27
February 2017). In total, we excluded 1326 studies and assessed 26
as full text for eligibility. See Figure 1. Of these, we included nine
studies and excluded 16, as per our a priori objectives reported in
the protocol for this review (Walker 2014).
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Figure 1. : Study flow diagram
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We only identified one trial as a relevant ongoing study (
ISRCTN57842461); however results from that study hadnot been
published at the time of this review. Refer to Characteristics of
ongoing studies for more details about this trial. We located no
new studies by searching reference lists, as any relevant studies had
been identified in the electronic searching.
Included studies
Study design and setting
Nine studies met the inclusion criteria for this review (refer to
Characteristics of included studies), although only eight were suit-
able for meta-analyses (Bale 1997; Banks 1994a; Meaume 2003;
Payne 2009; Seeley 1999; Sopata 2002; Souliotis 2016; Thomas
1997). One study (Bale 1998) usedmultiple subgroup analyses for
which results may have been misleading (Deeks 2011). Therefore
we did not include Bale 1998 in the meta-analyses but considered
it important for the narrative description. Apart from Bale 1998,
the included studies were randomised controlled trials (RCTs)
with two arms, for a total of 483 participants. Health settings
comprised community, aged and palliative-care facilities. Six in-
cluded studies used an intention-to-treat (ITT) approach (Polit
2010), where there was limited or no participant loss following
randomisation (Bale 1998; Meaume 2003; Payne 2009; Seeley
1999; Sopata 2002; Thomas 1997). The remaining studies (Banks
1994a; Souliotis 2016), used a per-protocol approach, which po-
tentially contributed to bias in their studies (Polit 2010).Wemade
attempts to contact study authors to request additional informa-
tion about missing data but no further information was received.
Participants
Participants from included trials were recruited from:
• five centres (not specified) in the UK (Bale 1997);
• the community in the UK (Bale 1998; Thomas 1997), and
Greece (Souliotis 2016);
• aged care facilities in Belgium, France and Italy (Meaume
2003);
• a palliative care unit in Poland (Sopata 2002);
• a combination of community, aged care and palliative
settings in the UK and USA (Banks 1994a; Payne 2009; Seeley
1999).
The mean age of participants in eight trials was ≥ 73 years (Bale
1997; Bale 1998; Banks 1994a;Meaume 2003; Payne 2009; Seeley
1999; Souliotis 2016; Thomas 1997). However the mean age of
participants was 59 years in Sopata 2002.
All included trials apart from Payne 2009 and Souliotis 2016 had
more female participants than male (Bale 1997; Bale 1998; Banks
1994a; Meaume 2003; Seeley 1999; Sopata 2002; Thomas 1997).
The most commonly reported locations for pressure ulcer were
the sacrum (Bale 1997; Banks 1994a; Meaume 2003; Payne 2009;
Seeley 1999; Souliotis 2016; Thomas 1997), hips and buttocks
(Payne 2009; Souliotis 2016; Thomas 1997), heel and ankle
(Meaume 2003; Seeley 1999; Souliotis 2016; Thomas 1997). Lo-
cation of pressure ulcer was not reported by Bale 1998 or Sopata
2002.
Interventions
We considered all types of dressing that were manufactured us-
ing foam as ’foam dressings’. Within the included studies these
consisted of hydrocellular foam (Bale 1998; Seeley 1999); hy-
dropolymer foam (Thomas 1997; Meaume 2003); polyurethane
foam (Bale 1997; Banks 1994a; Payne 2009; Sopata 2002); sili-
cone foam (Meaume 2003); as well as foam dressings with anti-
microbial (silver and silver-sulfadiazine), and analgesic (ibuprofen)
properties (Souliotis 2016). See Summary of outcomes, Table 3.
We considered foam dressings as a single group where possible.
Four studies compared a foam dressing with a hydrocolloid dress-
ing (Bale 1997; Bale 1998; Seeley 1999; Thomas 1997), three
compared foam dressing(s) with basic wound contact dressing
(Banks 1994a; Payne 2009; Souliotis 2016), one compared a foam
dressing with a hydrogel dressing (Sopata 2002) and one study
compared two different types of foam dressing (Meaume 2003).
Outcomes
A summary of reported outcomes relevant to the review is reported
in Table 3.
The primary outcome, incidence of healed pressure ulcer was
the most frequently reported (Bale 1997; Banks 1994a; Meaume
2003; Payne 2009; Seeley 1999; Sopata 2002; Thomas 1997), fol-
lowed by adverse events (Bale 1997; Meaume 2003; Seeley 1999;
Sopata 2002; Souliotis 2016;Thomas 1997), and time to complete
healing (Sopata 2002; Souliotis 2016). For secondary outcomes
five trials reported reduction in ulcer size (Bale 1998 Meaume
2003; Payne 2009; Sopata 2002; Thomas 1997), two reported
patient satisfaction (Bale 1998; Banks 1994a), and pain (Banks
1994a; Seeley 1999). None of the included studies reported out-
comes for quality of life or pressure ulcer recurrence. Economic
outcomes were reported in three trials (Bale 1998; Payne 2009;
Souliotis 2016).
Excluded studies
In total we excluded 16 studies from the review for the following
reasons (refer to Characteristics of excluded studies).
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• Where there was uncertainty about the classification system
used in studies, following contact or attempted contact with the
study authors, we deemed this a potential source of bias and did
not consider their inclusion. Four studies did not report the
classification system used to assess pressure ulcers (Banks 1994b;
Banks 1994c; Banks 1997; Reynolds 2004) and we were unable
to access the original data to clarify the classification used (Banks
1994b; Banks 1994c; Banks 1997), or contact the study author
(Reynolds 2004).
• Four studies were not RCTs or cluster-RCTs (Ashby 2012;
Diehm 2005; Oleske 1986; Parish 2008).
• Two studies did not report subgroup analyses for
participants with pressure ulcers in study arms comprising mixed
dressings (Münter 2006; Palao i Domenech 2008), and we were
unable to access original data (Münter 2006), or contact the
study authors (Palao i Domenech 2008).
• One study did not investigate or report a priori objectives
identified in the protocol for this review; that is, wound exudate
was the primary interest of the study and not the effectiveness of
the foam dressing in treating pressure ulcers (Piatkowski 2012).
• One pilot study was an RCT; however dressing choice in
the control group was based upon health professional and
participant choice (of which foam dressings were one option)
rather than randomisation (Ashby 2012).
• One study manuscript was incomplete and we could not
access it (Avanzi 2000).
• One study compared an intervention dressing comprising
hydrogel and foam layers with a hydrocolloid dressing. We
excluded the study as the hydrogel layer was closest to the skin,
and the foam was an outer layer that provided cushioning
(Brown-Etris 1996).
• One study compared two foams for the treatment of
pressure ulcers, however their application occurred as a
component of negative pressure wound therapy following
surgical debridement rather than as a wound dressing (Wagstaff
2014).
• One study included participants with neuropathic foot
ulcers, not pressure ulcers (Zimny 2003).
Risk of bias in included studies
Risk of bias was an important consideration when assessing the
quality of evidence reported in trials evaluated for this review as
reported in the ’Risk of bias’ summary (Figure 2) and ’Risk of bias’
graph (Figure 3).We have outlined our ’Risk of bias’ judgements in
the Characteristics of included studies. Eight of the nine included
studies were at high risk of bias for one or more domains. Overall,
the quality of reporting was limited due to lack of clarity and detail
as outlined below.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study
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Figure 3.
Allocation
We assessed three trials as being low risk of bias for random se-
quence generation (Banks 1994a; Meaume 2003; Seeley 1999),
with appropriate use of computer-generated randomisation lists.
The remaining six studies did not provide enough information
about the generation of a randomising sequence (Bale 1997; Bale
1998; Payne 2009; Sopata 2002; Souliotis 2016; Thomas 1997).
We judged only Banks 1994a, Meaume 2003, Seeley 1999 and
Souliotis 2016 tohave a low risk of bias for allocation concealment.
The remaining trials we assessed as having unclear risk of bias (Bale
1997; Bale 1998; Sopata 2002) or high risk of bias (Payne 2009;
Thomas 1997).
Blinding
While it is difficult to blind participants and personnel in stud-
ies where there was a physical evidence of treatment allocation,
there was no indication of blind-to-intervention assessment. As
such, we did not assess any trials as being at low risk of bias for
blinding of participants, personnel or outcome assessment of re-
ported outcomes relevant to this review. We assessed five trials
as having a high risk of bias for blinding of personnel (Meaume
2003; Payne 2009; Seeley 1999; Souliotis 2016; Thomas 1997),
and seven trials as being high risk of bias for blinding of outcome
assessment (Bale 1998; Meaume 2003; Payne 2009; Seeley 1999;
Sopata 2002; Souliotis 2016; Thomas 1997). The bias aspect of
the remaining studies we considered to be unclear (Bale 1997;
Banks 1994a).
Incomplete outcome data
We assessed six studies as being at low risk of attrition bias (Bale
1998; Meaume 2003; Payne 2009; Seeley 1999; Sopata 2002;
Thomas 1997) as they used an ITT approach (Polit 2010) where
there was no participant loss following randomisation or missing
data were unlikely to be related to the true outcome (Higgins
2011b). We judged other studies to have an unclear risk of bias, as
they used a per-protocol approach, which potentially contributed
to bias (Souliotis 2016), or reported incomplete outcome data
with insufficient descriptions for follow-up and comparator data
(Banks 1994a). We assessed one trial (Bale 1997) as being at high
risk of bias for incomplete outcome data, with a significant loss
of 67% of participants from the study. The study did not report
the number of participants who required a dressing change due to
discomfort and provided little detail regarding time to complete
wound healing.
Selective reporting
We judged four trials to be at low risk of bias for selective report-
ing (Bale 1997; Meaume 2003; Seeley 1999; Sopata 2002). The
remaining studies we considered to be at unclear risk of reporting
bias.
Other potential sources of bias
Other potential sources of bias included: acknowledgment that
dressing wearing time was not a true reflection of the average
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(unclear risk of bias) (Seeley 1999); and inequality of wound sizes
between groups (high risk of bias) (Bale 1998; Banks 1994a).
Indeed Bale 1998 undertook subgroup analyses in a subset of the
trial population, hence results may be misleading as they were not
based on randomised comparisons (Deeks 2011).
Effects of interventions
See: Summary of findings for the main comparison
Hydropolymer foam dressing compared with silicone foam
dressing for treating pressure ulcers; Summary of findings 2
Foam dressings compared with hydrocolloid dressings for treating
pressure ulcers; Summary of findings 3 Foam dressing compared
with hydrogel dressing for treating pressure ulcers; Summary of
findings 4 Foam dressings compared with basic contact dressings
for treating pressure ulcers
We have organised findings by comparison and a priori outcome
measures as outlined above (Types of outcome measures).
The nine trials included 483 participants. The trials were small
(median sample size = 20), and while there was some clinical and
methodological heterogeneity, we undertook meta-analysis where
there was similarity between dressings (intervention foam versus
comparator hydrocolloid), follow-up periods and category/stages
of pressure ulcer subgroups. Where there was no similarity, we
summarised studies narratively.
Comparison 1: hydropolymer foam dressing
compared with silicone foam dressing (1 trial; 38
participants)
Only one trial compared a foam dressing (hydropolymer foam)
with another foam dressing (silicone foam) (Meaume 2003) with
8 weeks of follow-up.
Primary outcomes
Incidence of healed pressure ulcers (short-term follow-up, 8
weeks or less)
It is uncertain whether alternative types of foam dressing affected
the incidence of healed pressure ulcers over a short-term follow-
up period: RR 0.89 (95% CI 0.45 to 1.75) (Analysis 1.1). The
certainty of evidence was very low due to high risk of bias, down-
graded once due to serious limitations in design and implemen-
tation (lack of blinding) and twice for very serious imprecision of
results due small sample size and wide confidence intervals. See
Summary of findings for the main comparison.
Meaume 2003 did not report our primary outcome: time to com-
plete healing
Adverse events (short-term follow-up, 8 weeks or less)
It is uncertain whether alternative types of foam dressing affected
the risk of adverse events in people with pressure ulcers: RR 0.37
(95% CI 0.04 to 3.25) (Analysis 1.2). The certainty of evidence
was very low due to high risk of bias, downgraded once due to
serious limitations in design and implementation (lack of blinding)
and twice for very serious imprecision of results due to low number
of events and wide confidence intervals. See Summary of findings
for the main comparison.
Secondary outcomes
Reduction in ulcer size (short-term follow-up, 8 weeks or
less)
Reduction of wound size wasmeasured in cm2 from tracings of the
each participant’swound at baseline andfinal assessment (Meaume
2003).Wounds dressedwith the silicone foamdressing had amean
reduction in wound area of 3.1 cm2 compared with 3.3 cm2 in the
hydropolymer foam dressing. No standard deviation or standard
error data were reported and so could not be analysed further. We
assessed the evidence as very low certainty due to high risk of bias,
downgraded once due to imitations in design and implementation
(lack of blinding) and twice for very serious imprecision of results
due to small sample size and lack of reporting.
Meaume 2003 did not report the secondary outcomes quality of
life, patient satisfaction/acceptability or pressure ulcer recurrence
and pain, or the economic outcomes, cost, utility scores represent-
ing health-related quality of life and incremental cost per event.
Comparison 2: foam* dressings compared with
hydrocolloid dressings (4 trials; 230 participants)
*Hydrocellular, hydropolymer and polyurethane foam dressings
This comparison included four trials with 230 participants (Bale
1997; Bale 1998; Seeley 1999; Thomas 1997). All the studies had
short-term follow-up (up to 8 weeks). It should be noted that
Bale 1997 and Bale 1998 were both conducted in community set-
tings that were not specifically described, and used the same dress-
ings: hydrocolloid versus foam (described as a polyurethane foam
dressing in Bale 1997 and a hydrocellular dressing in Bale 1998).
However, reported sample sizes between the studies were differ-
ent as was the focus. Bale 1997 focused on “ease of application,
removal, adhesion, conformability, absorbency and wear time”,
whereas Bale 1998 compared the costs of dressing and “dressing
durability, time to competed healing, ease of wound cleansing and
dressing removal.”
Primary outcomes
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Incidence of healed pressure ulcers (short-term follow-up, 8
weeks or less)
Only three trials reported incidence of healed pressure ulcers in
this comparison (Bale 1997; Seeley 1999; Thomas 1997), while
Bale 1998 primarily reported costs associated with the dressings.
Follow-up times ranged from four weeks (Bale 1997), six weeks
(Thomas 1997) and eight weeks (Seeley 1999). It is uncertain
whether foam dressings affected the incidence of healed pressure
ulcers compared with hydrocolloid dressings over a short-term
period: RR 0.85 (95%CI 0.54 to 1.34) (Analysis 2.1).We assessed
this as very low-certainty evidence, downgraded twice due to very
serious limitations in design and implementation (lack of blinding
and allocation concealment) and once for very serious imprecision
of results due small sample size and wide confidence intervals. See
Summary of findings 2.
None of the trials included in this comparison reported time to
complete healing (Bale 1997; Seeley 1999; Thomas 1997)
Adverse events (short-term follow-up, 8 weeks of less)
Three studies reported dressing-related adverse events (Bale 1997;
Seeley 1999; Thomas 1997). It is uncertain whether foam dress-
ings affected the risk of adverse events compared with hydrocol-
loid dressings RR 0.88 (95% CI 0.37 to 2.11) (Analysis 2.2). The
certainty of evidence was very low due to high risk of bias, down-
graded once due to limitations in design and implementation (lack
of blinding and allocation concealment) and twice for very serious
imprecision of results due small sample size and wide confidence
intervals. See Summary of findings 2.
Bale 1998 reported adverse events. However these data were not
separated by wound type. It is uncertain whether foam dressings
affected the risk of adverse events compared with hydrocolloid
dressings because we assessed the quality of the evidence as being
very low due to high risk of bias, and downgraded twice due to
limitations in design and implementation (uncertain blinding and
allocation concealment) and once for imprecision of results due
to small sample size and incomplete reporting.
Secondary outcomes
Reduction in ulcer size (short-term follow-up, 8 weeks or
less)
Two studies (Bale 1998; Thomas 1997) (n = 131) reported on
reduction in ulcer size.However datawere not separated bywound
type in both studies preventing further analysis. It is uncertain
whether foam dressings led to reduction in ulcer size compared to
hydrocolloid dressings because the quality of the evidence was very
low due to high risk of bias, downgraded twice due to limitations
in design and implementation (lack of blinding and allocation
concealment) and once for imprecision of results due to small
sample size and lack of reporting.
Bale 1997 and Seeley 1999 did not report reduction in ulcer size.
None of the trials included in this comparison reported our sec-
ondary outcome, quality of life (Bale 1997; Bale 1998; Seeley
1999; Thomas 1997)
Patient satisfaction/acceptability (short-term follow-up, 8
weeks or less)
Bale 1998 reported patient satisfaction based on the comfort of
the foam and hydrocolloid dressings. However these data were
not separated by wound type. It is uncertain whether foam dress-
ings led to patient satisfaction/acceptability because we assessed
the certainty of the evidence as being very low due to high risk
of bias, and downgraded twice due to limitations in design and
implementation (uncertain blinding and allocation concealment)
and once for imprecision of results due to small sample size and
incomplete reporting.
Bale 1997; Seeley 1999 and Thomas 1997 did not report patient
satisfaction/acceptability.
None of the four trials reported secondary outcome pressure ulcer
recurrence.
Pain (short-term follow-up, 8 weeks or less)
Seeley 1999 used a 4-point rating scale (0 = none, 1 = mild, 2
= moderate, 3 = severe) to assess wound pain. It is uncertain if
the foam dressing affected wound pain (mean 0.15, SD 0.8, n =
20) compared with the hydrocolloid dressing (MD -0.32, 95%
CI -0.86 to 0.22) (Analysis 2.3). Thomas 1997 recorded pain and
discomfort associated with the dressing (comfortable or otherwise
and reported P = 0.023) however did not report any further de-
tails. It is uncertain whether the foam dressings led to pain com-
pared with the hydrocolloid dressing because the certainty of the
evidence was very low for both studies due to high risk of bias,
downgraded twice due to limitations in design and implementa-
tion (lack of blinding), and once for imprecision of results.
Economic outcomes
Costs and incremental cost per event (short-term follow-up,
8 weeks or less)
Bale 1998 compared the material costs for foam and hydrocol-
loid dressing changes, which included costs of dressing and saline.
Costs were reported as GBP using a 1994 cost year. The total cost
of treatment was GBP 844 (mean GBP 50 per participant, n = 17)
for using the foam dressing compared to GBP 1142 (mean GBP
76 per participant, n = 15) for the hydrocolloid dressing. However,
these costs related to an already small participant subgroup (n =
32) and the authors did not report the statistical significance of the
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difference. In addition, they did not include the costs of nursing
time for the dressing change or management of complex wounds
and participants in the hydrocellular group were more likely to
have a less severe stage of pressure ulcer at enrolment, representing
a significant limitation of the study.
Although Bale 1998 reported healing rates in addition to mate-
rials costs for dressing changes, the study authors did not draw
conclusions regarding the cost-effectiveness of foam dressings for
themanagement of pressure ulcers, which is appropriate given this
analysis was based on a small subgroup sample without tests of
statistical significance and with only partial costs included. This
study had very low-certainty evidence due to high risk of bias,
downgraded twice due to limitations in design and implementa-
tion (lack of blinding and allocation concealment), and once for
imprecision of results due to small sample size and lack of report-
ing.
The other studies in this comparison (Bale 1997; Seeley 1999;
Thomas 1997) did not report economic outcomes.
Comparison 3: polyurethane foam dressing compared
with hydrogel dressing (1 trial; 34 participants)
Sopata 2002 compared a foam dressing with a hydrogel dressing,
with a short-term follow-up period of eight weeks.One participant
in the foam dressing group had two pressure ulcers and one or
more participants in the hydrogel dressing group had more than
one wound, which we could not specify through communication
with the study author.We allocated one wound to each participant
in the analysis. See Summary of findings 3.
Primary outcomes
Incidence of healed pressure ulcers (short-term follow-up, 8
weeks or less)
It is uncertain whether treatment with a foam dressing affected
the incidence of healed pressure ulcers compared with a hydrogel
dressing: RR 1.00 (95% CI 0.78 to 1.28) (Analysis 3.1). We as-
sessed the evidence as very low certainty due to high risk of bias,
downgraded once due to limitations in design and implementa-
tion (lack of blinding) and twice for very serious imprecision of
results due small sample size and wide confidence intervals. See
Summary of findings 3.
Time to complete healing (short-term follow-up, 8 weeks or
less)
This study (n = 34) reported treatment times in days (mean ± SD).
Compared to the hydrogel dressings, foam dressings were associ-
ated with an increased number of treatment days MD 5.67 days,
(95%CI -4.03 to 15.37) (Analysis 3.2), although this increase was
not statistically significant. This was very low certainty evidence
due to high risk of bias, downgraded once due to limitations in
design and implementation (lack of blinding) and twice for serious
imprecision of results due small sample size and wide confidence
intervals. See Summary of findings 3.
Adverse events (short-term follow-up, 8 weeks or less)
One adverse event was reported in the hydrogel dressing group
(1/17) where the Category/Stage II pressure ulcer increased in
size. It is uncertain whether use of a foam dressing affected the
incidence of adverse events compared with a hydrogel dressing:
RR 0.33 (95% CI 0.01 to 7.65) (Analysis 3.3). This was very low-
certainty evidence due to high risk of bias, downgraded once due
to limitations in design and implementation (lack of blinding) and
twice for very serious imprecision of results due small sample size
and wide confidence intervals. See Summary of findings 3.
Secondary outcomes
Reduction in ulcer size per day (short-term follow-up, 8
weeks or less)
Sopata 2002 reported reduction of ulcer size for healed pressure
ulcers only (n = 30). The mean difference was 0.30 cm2 per day
(95% CI -0.15 to 0.75) (Analysis 3.4). It is uncertain whether
treatment with foam or hydrogel dressings had any impact on
the reduction of pressure ulcer size. This trial did not report total
overall reduction in ulcer size nor its categorised treatment effect;
rather it reported the duration of treatment time by day. While
Sopata 2002 compared wound healing rates with Banks 1994a, no
supporting data were presented. We assessed the evidence as very
low certainty due to high risk of bias, downgraded once due to
limitations in design and implementation (lack of blinding) and
twice for very serious imprecision of results due to small sample
size, wide confidence interval and incomplete reporting.
Sopata 2002 did not report our secondary outcomes, quality of
life, patient satisfaction/acceptability, pressure ulcer recurrence
and pain, or economic outcomes, cost, utility scores representing
health-related quality of life and incremental cost per event.
Comparison 4: foam dressings* compared with basic
wound contact dressings** (3 trials; 181 participants)
*Polyurethane, silver and ibuprofen-releasing foam dressing
** Gauze, saline-soaked gauze, low-adherence dressing secured by
a vapour-permeable film
Three trials (Banks 1994a; Payne 2009; Souliotis 2016) compared
foamdressings with basic wound contact dressings (plain or saline-
soaked gauze and knitted multi-filament yarns secured with a
vapour-permeable film). Follow-up times ranged from short-term
(4 weeks for Payne 2009) and medium term (12 weeks for Banks
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1994a and just over 17 weeks for Souliotis 2016). See Summary
of findings 4.
Primary outcomes
Incidence of healed pressure ulcers (short-term follow-up, 8
weeks or less)
Using data from one study (Payne 2009) (n = 36) it is uncertain if
there is a difference in the incidence of healed pressure ulcers over
a short-term follow-up period: RR 1.33 (95% CI 0.62 to 2.88)
(Analysis 4.1). We assessed the evidence as very low certainty due
to high risk of bias, downgraded once because of limitations in
design and implementation (lack of blinding) and twice for seri-
ous imprecision of results due small sample size, wide confidence
intervals and incomplete reporting. See Summary of findings 4.
Incidence of healed pressure ulcers (medium-term follow-up,
8 to 24 weeks)
Using data from Banks 1994a (n = 50), it is uncertain whether
foam dressings impact on the incidence of healed pressure ulcers
compared with the control dressing consisting of a layer of knit-
ted viscous multifilament yarns: RR 1.17 (95% CI 0.79 to 1.72)
(Analysis 4.1). We also assessed this evidence as very low certainty
due to high risk of bias, downgraded once due to limitations in
design and implementation (lack of blinding) and twice for seri-
ous imprecision of results due small sample size, wide confidence
intervals and incomplete reporting. See Summary of findings 4.
Souliotis 2016 did not report incidence of healed pressure ulcers.
Time to complete healing (medium-term follow-up, 8 to 24
weeks)
Souliotis 2016 (n = 95) reported all participants achieving com-
plete wound healing within 24 weeks (17.3 weeks). This study re-
ported time to complete healing in days (mean ± SD). Compared
to basic contact dressings, we observed that in this single study,
foam dressings were associated with a decreased time to complete
healingMD -35.8 days, (95%CI -56.77 to -14.83) (Analysis 4.2).
However this was very low certainty evidence due to high risk of
bias, downgraded once due to limitations in design and imple-
mentation (lack of blinding) and twice for serious imprecision of
results due small sample size, wide confidence intervals and in-
complete reporting. See Summary of findings 4.
Banks 1994a and Payne 2009 did not report our primary outcome,
time to complete healing.
Adverse events (medium-term follow-up, 8 to 24 weeks)
Souliotis 2016 reported 12 adverse events-related wound infec-
tions in the foam dressings group (n = 48), compared with 21
in the basic wound contact dressing group: RR 0.58 (95% CI
0.33 to 1.05) Analysis 4.3. Hence more adverse events related to
wound infection occurred in the basic wound contact dressing
group, compared to the foam dressing group. This was low-cer-
tainty evidence, due to high risk of bias, downgraded once due to
limitations in design and implementation (lack of blinding) and
twice for serious imprecision of results due small sample size, wide
confidence intervals and incomplete reporting. See Summary of
findings 4.
Banks 1994a and Payne 2009 did not report the primary outcome,
adverse events.
Secondary outcomes
Reduction in ulcer size (short-term follow-up, 8 weeks or
less)
Payne 2009 (n = 36) documented the size of participants’ ulcers
in cm2 as a baseline in the polyurethane foam and saline-soaked
gauze dressing groups, however did not report the final assessment
of wound size to enable comparison. It is uncertain whether foam
dressings led to a reduction in ulcer size compared with basic
wound contact dressings. This was very low-certainty evidence
due to high risk of bias, downgraded twice due to limitations
in design and implementation (lack of blinding) and once for
serious imprecision of results due small sample size and incomplete
reporting.
Banks 1994a and Souliotis 2016 did not report the secondary
outcome, reduction in ulcer size.
Patient satisfaction/acceptability (medium-term follow-up, 8
to 24 weeks)
Banks 1994a (n = 50) used a patient acceptance questionnaire to
record dressing comfort using a scale from 0 = poor to 10 = very
comfortable. While they reported mean scores, they did not pro-
vide any other information, such as standard deviation or variance
data, from which we could make a meaningful interpretation. It
is uncertain whether foam dressings affected patient satisfaction/
acceptability compared with basic wound contact dressings. We
assessed the evidence as very low certainty due to high risk of bias,
downgraded twice due to limitations in design and implemen-
tation (lack of blinding) and once for imprecision of results due
small sample size and incomplete reporting.
Payne 2009 and Souliotis 2016 did not report our secondary out-
come, patient satisfaction/acceptability.
Pain (medium-term follow-up, 8 to 24 weeks)
Banks 1994a also used a patient acceptance questionnaire to record
pain on dressing removal using a scale from 0 = painful to 10 =
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painless. While they reported mean scores, they did not provide
any other information, such as standard deviation or variance data,
from which we could make a meaningful interpretation. It is un-
certain whether foam dressings affected pain compared with basic
wound contact dressings. This was very low-certainty evidence due
to high risk of bias, downgraded twice due to limitations in design
and implementation (lack of blinding) and once for imprecision
of results due small sample size and incomplete reporting.
Payne 2009, Souliotis 2016 and Thomas 1997 did not report our
secondary outcome, pain.
Banks 1994a; Payne 2009; Souliotis 2016 did not report our sec-
ondary outcome, quality of life.
Economic outcomes
Cost and incremental cost per event (short-term follow-up,
up to 8 weeks)
Payne 2009 (n = 36) analysed treatment costs (dressings, other ma-
terials, and nurse time) until ulcer healing or 28 days, whichever
occurred first. They reported costs as USD using a cost year of
2006/7. The polyurethane foam dressing was less costly per par-
ticipant (USD 315) than saline-soaked gauze (USD 781), repre-
senting a mean saving of USD 466 per participant in the foam
group (P = 0.055). The study authors reported the foam dressing
to be dominant; that is, less costly and more effective in terms of
number of participants healed by 28 days and ulcer-free days per
participant. They concluded that the foam dressing was cost ef-
fective compared to saline-soaked gauze for the treatment of Cate-
gory/Stage II pressure ulcers. However, the study was not powered
to detect differences in time to healing nor sensitivity analyses un-
dertaken for participants who withdrew before their wounds had
healed or before the treatment period. Due to a lack of data, ad-
ditional analysis was not possible and we are uncertain about the
relative impact of basic wound contact dressings on economic out-
comes compared with foam dressings. We assessed this evidence
as very low certainty due to high risk of bias, downgraded twice
due to limitations in design and implementation (lack of blinding)
and once for serious imprecision of results due small sample size.
Costs and incremental cost per event (medium-term follow-
up, 8 to 24 weeks)
Souliotis 2016 reported total and per-participant treatment costs
in the home setting until healing (including dressings, labour and
materials). The cost year was not stated. Treatment costs over the
study period (to ulcer healing) indicated foam dressings were less
costly overall (EUR 63,543 for 47 participants) and per partici-
pant (EUR 1351) than plain gauze overall (EUR 186,638 for 48
participants) or per participant (EUR 3888). However, they did
not report the statistical significance of this difference. Therefore,
although the study authors also reported a shorter average healing
time for the foam dressing than the gauze dressing group, it is not
possible to draw strong conclusions around cost effectiveness. A
paucity of data prevented further analysis and we are uncertain
about the relative impact of foam dressings on economic outcomes
compared with basic wound contact dressings. This was very low-
certainty evidence due to high risk of bias, downgraded once due
to limitations in design and implementation (lack of blinding) and
twice for serious imprecision of results due to small sample size
and incomplete reporting.
Banks 1994a did not report economic outcomes.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Foam dressings compared with hydrocolloid dressings for treating pressure ulcers
Patient or population: people of any age with an exist ing pressure ulcer of Category/ Stage II or above
Settings: any care sett ing
Intervention: hydrocellular, hydropolymer and polyurethane foam dressings
Comparison: hydrocolloid dressing
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
Heterogeneity No of participants
(studies)
Quality of the evi-
dence
(GRADE)
Comments
Risk with hydrocol-
loid dressing
Risk with foam
dressing
Incidence of heal-
ing, short- term fol-
low-up (8 weeks or
less)
293 per 1000 249 per 1000
( 158 to 393 )
RR 0.85
(0.54 to 1.34)
Chi2 = 2.12, df = 2,
(P = 0.35), I2 = 6%
198
(3 RCTs)
⊕©©©
very low1
Time to complete
healing
Outcome not mea-
sured or reported for
this comparison
Outcome not mea-
sured or reported for
this comparison
n/ a - n/ a Outcome not mea-
sured or reported for
this comparison
Ad-
verse events, short-
term follow-up (8
weeks or less)
91 per 1000 81 per 1000
(34 to 192)
RR 0.88
(0.37 to 2.11)
Chi2 = 0.82, df = 2,
(P = 0.66), I2 = 0.0%
198
(3 RCTs)
⊕©©©
very low2
A fourth RCT re-
ported ad-
verse events. How-
ever these data were
not separated by
wound type
Quality of life Outcome not mea-
sured or reported for
this comparison
Outcome not mea-
sured or reported for
this comparison
n/ a - n/ a Outcome not mea-
sured or reported for
this comparison
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* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: conf idence interval; RR: risk rat io
GRADE Working Group grades of evidence
High quality: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate quality: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1Majority of evidence at very high risk of bias due to lim itat ions in design and implementat ion due to lack of blinding and
allocat ion concealment (downgraded twice); serious imprecision of results due to small sample size and wide conf idence
intervals (0.54 to 1.34) (downgraded once).
2Majority of evidence at high risk of bias due to lim itat ions in design and implementat ion due to lack of blinding and allocat ion
concealment (downgraded once); very serious imprecision of results due small sample size and wide conf idence intervals
(0.37 to 2.11) (downgraded twice).
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Foam dressing compared with hydrogel dressing for treating pressure ulcers
Patient or population: people of any age with an exist ing pressure ulcer of Category/ Stage II or above
Settings: any care sett ing
Intervention: polyurethane foam dressing
Comparison: hydrogel dressing
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with hydrogel
dressing
Risk with foam dress-
ing
Incidence of healing,
short- term follow-up
(8 weeks or less)
882 per 1000 882 per 1000
(159 to 1129)
RR 1.00 (0.78 to 1.28) 34 (1 RCT) ⊕©©©
very low1
Time to complete heal-
ing
Treatment t ime re-
ported in days reported.
The medium time was
20.10 days (for 20
wounds)
Treatment t ime re-
ported in days reported.
The medium time was
5.67 days more days (4.
03 to 15.37 days more,
for 18 wounds)
n/ a 34 (1 RCT) ⊕©©©
very low2
Adverse events, short-
term follow-up
(8 weeks or less)
59 per 1000 20 per 1000
(1 to 450)
RR 0.33 (0.01 to 7.65) 34 (1 RCT) ⊕©©©
very low3
Quality of life Outcome not measured
or reported for this
comparison
Outcome not measured
or reported for this
comparison
n/ a n/ a Outcome not measured
or reported for this
comparison
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: conf idence interval; RR: risk rat io
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GRADE Working Group grades of evidence
High quality: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate quality: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1Majority of evidence at high risk of bias due to lim itat ions in design and implementat ion due to lack of blinding (downgraded
once); very serious imprecision of results due to small sample size and wide conf idence intervals (0.78 to 1.28) (downgraded
twice).
2Majority of evidence at high risk of bias due to lim itat ions in design and implementat ion due to lack of blinding (downgraded
once); very serious imprecision of results due to small sample size, wide conf idence intervals (-4.03 to -15.37) (downgraded
twice).
3Majority of evidence at high risk of bias due to lim itat ions in design and implementat ion due to lack of blinding (downgraded
once); very serious imprecision of results due small sample size and wide conf idence intervals (0.0.1 to 7.65) (downgraded
twice).
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Foam dressings compared with basic contact dressings for treating pressure ulcers
Patient or population: people of any age with an exist ing pressure ulcer Category/ Stage II or above
Settings: any care sett ing
Intervention: polyurethane, silver and ibuprofen-releasing foam dressings
Comparison: basic contact dressings (gauze, saline-soaked gauze, low-adherence dressing secured by a vapour-permeable f ilm)
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
Subgroup differ-
ences
No of participants
(studies)
Quality of the evi-
dence
(GRADE)
Comments
Risk with basic con-
tact dressings
Risk with foam
dressing
Incidence of heal-
ing, short- term fol-
low-up (8 weeks of
less)
375 per 1000 500 per 1000
(233 to 1080)
RR 1.33 (0.62 to 2.
88)
Chi2 = 0.09, df = 1,
(P = 0.77), I2 = 0.0%
36 (1 RCT) ⊕©©©
very low1
Incidence of heal-
ing, medium- term
follow-up (8 to 24
weeks)
625 per 1000 731 per 1000
(494 to 1075)
RR 1.17 (0.79 to 1.
72)
50 (1 RCT) ⊕©©©
very low2
Time to com-
plete healing (days)
medium- term fol-
low-up (8 to 24
weeks)
The mean time
to complete heal-
ing (days) was 121.
4 days
The mean time
to complete healing
with foam dressing
was 35.80 days less
(56.77 to 14.83 less)
95 (1 RCT) ⊕©©©
very low3
Adverse events,
medium- term fol-
low-up (8 to 24
weeks)
438 per 1000 254 per 1000
(145 to 460)
RR 0.58 (0.33 to 1.
05)
95 (1 RCT) ⊕⊕©©
low4
Quality of life Outcome not mea-
sured or reported for
this comparison
Outcome not mea-
sured or reported for
this comparison
n/ a n/ a Outcome not mea-
sured or reported for
this comparison29
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Incremental cost
per event, short-
term follow-up (8
weeks or less)
Per pat ient cost USD
781
Per pat ient cost USD
315
n/ a 36 (1 RCT) ⊕©©©
very low5
Cost dif -
ference between in-
tervent ion and com-
parator dressings =
USD 466
Treatment cost data
for intervent ion and
comparator dress-
ings, other materi-
als and nurse t ime
based on nat ional
standard costs in
the USA in mid-2007
and hourly wages
for nurses based on
2006 rates
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: conf idence interval; RR: risk rat io
GRADE Working Group grades of evidence
High quality: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate quality: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1Majority of evidence at high risk of bias due to lim itat ions in design and implementat ion due to lack of blinding (downgraded
once); very serious imprecision of results due to small sample size, wide conf idence intervals and incomplete report ing
(0.62 to 2.88) (downgraded twice)
2Majority of evidence at high risk of bias due to lim itat ions in design and implementat ion due to lack of blinding (downgraded
once); very serious imprecision of results due to small sample size, wide conf idence intervals and incomplete report ing (0.79
to 1.72) (downgraded twice)
3Majority of evidence at high risk of bias due to lim itat ions in design and implementat ion due to lack of blinding (downgraded
twice); very serious imprecision of results due to small sample size, wide conf idence intervals and incomplete report ing
(-56.77 to -14.835) (downgraded once).
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4Majority of evidence at high risk of bias due to lim itat ions in design and implementat ion due to lack of blinding (downgraded
once); very serious imprecision of results due to small sample size, wide conf idence levels and incomplete report ing (0.33 to
1.05) (downgraded once).
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
3
1
F
o
a
m
d
re
ssin
g
s
fo
r
tre
a
tin
g
p
re
ssu
re
u
lc
e
rs
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
7
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
D I S C U S S I O N
Summary of main results
This review of nine trials with 483 participants includes all the cur-
rently available RCT evidence evaluating foam dressings to treat
pressure ulcers. The primary outcomes for this review were inci-
dence of healed pressure ulcers, time to complete healing and ad-
verse events per participant. Secondary outcomes included reduc-
tion in ulcer size, quality of life, patient satisfaction/acceptability,
pressure ulcer recurrence, and pain. None of the included trials
reported quality of life or pressure ulcer recurrence.We also sought
economic outcomes, such as cost, utility scores and incremental
costs.
We assessed trials according to the following comparisons: 1) dif-
ferent types of foam dressings compared with each other (1 trial,
38 participants); 2) foam dressings compared with hydrocolloid
dressings (4 trials; 230 participants); 3) foam dressings compared
with hydrogel dressings (1 trial; 34 participants) and; 4) foam
dressings compared with basic wound contact dressings (3 trials;
181 participants).
We judged GRADE assessments as being of low to very low cer-
tainty due to serious risk of bias related to lack of blinding and
allocation concealment, and imprecision due to small samples or
lack of data, or both. Overall, themajority of evidence for all of the
included trials was at high risk of bias due to limitations in design
and implementation (related to lack of blinding or allocation con-
cealment, or both) and serious imprecision of results (related to all
or a combination of small sample size, wide confidence intervals
and lack of reporting). Hence we can draw no firm conclusions
about clinical advantages, cost effectiveness or patient satisfaction/
acceptability between the different types of foam dressings or foam
dressing compared with other dressings.
More specifically, we found uncertain evidence about whether
foam dressings presented any substantial clinical advantages when
compared with other dressings in terms of impact on incidence
of pressure ulcers, increasing the time to healing of pressure ulcer,
preventing adverse events associated with pressure ulcers, or re-
ducing the size of pressure ulcers. There was also limited available
evidence on which to draw conclusions about the comparative im-
pacts of foam dressings for pressure ulcers on quality of life, pain,
and satisfaction and acceptability for participants. Available cost
evaluations also provided low-certainty evidence due to missing
data and absence of cost-benefit analyses that would benefit deci-
sion makers.
Overall completeness and applicability of
evidence
Overall, there were significant weaknesses in the completeness and
approachability of evidence reported in the included studies. The
trials had small samples (median sample size = 20), and there was
no evidence of replication of studies or progression to larger trials,
hence comparisons were limited.
There was an overlap of investigators in the teams of four trials
(Bale 1997; Bale 1998; Banks 1994a; Thomas 1997). These trials
are dated by 20 or more years, hence we were unable to contact
the study authors with requests for additional information. Where
we were able to contact study authors, they no longer had access
to data or could not recall details of individual trials (Bale 1997;
Bale 1998; Banks 1994a; Sopata 2002; Thomas 1997). Apart from
an included trial published in 2016, the date of publication for
the remaining eight trials (1994 to 2009), may also explain the
absence of a standardised approach (such as CONSORT (Schulz
2010)), to report methods and results. Consequently, there was
a high degree of variability between studies in terms of dress-
ings used, follow-up periods, interventions and outcomes. Simi-
larly there was methodological diversity due to: selection bias re-
lated to the generation of randomisation sequences (Bale 1998;
Payne 2009; Sopata 2002; Souliotis 2016;Thomas 1997); allo-
cation concealment (Bale 1997; Bale 1998; Payne 2009; Sopata
2002; Thomas 1997); lack of blinding of participants and per-
sonnel (Meaume 2003; Payne 2009; Seeley 1999; Sopata 2002;
Souliotis 2016); outcome assessment (Bale 1998; Meaume 2003;
Payne 2009; Seeley 1999; Sopata 2002; Souliotis 2016; Thomas
1997); and attrition bias (Bale 1997). While we acknowledge that
it is difficult to blind participants and personnel in studies where
there is a physical evidence of treatment allocation, none of the
eight included studies demonstrated blind-to-intervention assess-
ment.
Six trials did not report a funding source (Banks 1994a; Meaume
2003; Seeley 1999; Sopata 2002; Souliotis 2016; Thomas 1997).
However the authors of three trials, acknowledged industry spon-
sorship (Bale 1997; Bale 1998; Payne 2009). Sponsorship was also
disclosed in half of the excluded trials (Banks 1994b; Banks 1994c;
Münter 2006; Palao i Domenech 2008; Parish 2008; Piatkowski
2012; Reynolds 2004; Wagstaff 2014).
Quality of the evidence
The body of evidence from this review cannot provide robust con-
clusions regarding the objectives. Hence its downgrade to low or
very low-certainty evidence related to risk of bias and imprecision.
• Risk of bias was evident due to small study samples,
unblinded outcome assessment, and occasional selective
reporting. None of the included studies actively tried to avoid
performance bias, although this may be a defendable action due
to the difficulty of allocation concealment inherent in wound
studies. All of the studies in the review failed to report time to
complete healing, quality of life, pressure ulcer recurrence, and
economic outcomes utility score representing health-related
quality of life, or incremental costs per event. These are
important outcomes that could provide essential information for
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health policy makers to ensure cost-effective, patient-focused
care.
• Included trials were small and underpowered with wide
confidence intervals indicating imprecision in the point
estimates, leading to very little confidence in the estimate of
effect. Most included trials had relatively short to medium
follow-up times (mean 8 weeks), which led to imprecise results.
RCTs need to be adequately powered for treatment effects to be
detected. Sample size calculations help estimate the number of
participants required. Trials should also have an appropriate
follow-up period to enable important outcome measures (such as
wound healing) to occur.
Potential biases in the review process
The review considered the evidence that it was possible to obtain
and included studies that were not published in English-language
journals. It is possible that there may be unpublished data that we
have not been able to access, as well a potential for publication
bias; however, this is very unlikely given the range of findings from
this review. There were deviations from the protocol based on a
posteriori conditions related to alternative pressure ulcer classifica-
tion systems, namely the Stirling (Reid 1994) and Torrence classi-
fication systems (Harker 2000), and earlier versions published by
the NPUAP (NPUAP 1989), that deviated form the contempo-
rary International NPUAP/EPUAP/PPPIA Pressure Ulcer Classi-
fication System Criteria (NPUAP/EPUAP/PPPIA 2014). We ac-
cepted these alternative classification systems on the condition that
the definitions of stage/grade closely matched the contemporary
International NPUAP/EPUAP/PPPIA Pressure Ulcer Classifica-
tion System Criteria (NPUAP/EPUAP/PPPIA 2014). See Table 2
for a comparison of pressure ulcer classification systems. We also
included studies that recruited participants with Category/Stage
II pressure ulcers or above alongside people with other types of
chronic wounds, such as venous and arterial leg ulcers or diabetic
foot ulcers, if the results for people with relevant pressure ulcers
were presented separately (or this data were available from study
authors). Similarly when a study included both Category/Stage I
and more advanced pressure ulcers, we included it in the review
only if data for Category/Stage II and above were reported sepa-
rately, or if the data were available on request from study authors.
We also included studies where pressure ulcers from Category/
Stage II and above were reported collectively. It was not possible to
evaluate the wider possibility of publication bias as there was vari-
ability of reporting between the included studies, and there were
challenges in contacting or sourcing additional information from
authors due to age of the studies. As a result of this heterogeneity,
we were only able to combine studies for comparison based on
their shared outcomes.
Agreements and disagreements with other
studies or reviews
Noother reviews have presented data on foam dressings as they are
presented here; however the findings of this review concur with
the conclusion of the large review by Reddy 2008, that looked at
several treatments for pressure ulcers and stated that, “No single
dressing was consistently superior to other dressings in the trials
of pressure ulcers we examined” (p. 2659). The recent National
Institute of Health and Clinical Effectiveness (NICE) Pressue Ul-
cer Guidelines state that “a dressing for adults that promotes a
warm, moist wound healing environment to treat Grade 2, 3 and
4 pressure ulcers” should be considered (NICE 2014). The guide-
lines further state that gauze dressings should not be offered to
treat a pressure ulcer in adults. We included all studies examined
in the NICE review and a further two studies not mentioned in
the NICE guidelines (Bale 1997; Banks 1994a).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
A comprehensive review of current evidence found no indication
of differential effects of foam dressings compared with alternative
wound treatments on the outcomes that matter for pressure ulcers
(including healing), or cost-effectiveness. We assessed all of the
review trials (Bale 1997; Bale 1998; Banks 1994a; Meaume 2003;
Payne 2009; Seeley 1999; Sopata 2002; Souliotis 2016 Thomas
1997) as having low- to very low-quality evidence due to risk of
bias stemming from unblinded outcome assessment, and occa-
sional selective reporting; inconsistent reporting and; imprecision
of results from small and underpowered trials, with relatively short
follow-up times (mean 8 weeks).
Health clinicians may therefore elect to consider other character-
istics of wound dressings for the treatment of pressure ulcers such
as cost, symptom management properties (such as exudate) and
context when choosing a suitable dressing.
Implications for research
There is an urgent need to evaluate the clinical and cost-effective-
ness of foam dressings to treat pressure ulcers. Currently there is
no evidence of a difference in ulcer healing between pressure ul-
cers dressed with foam dressings and those treated with the other
dressings that have been evaluated. In terms of dressing choice,
any investment in future researchmust maximise its value in terms
of clinical and cost-effectiveness to decision makers. Given the
large number of dressing options, the design of future trials should
be driven by high priority questions from patients and other de-
cision makers. It is also important for researchers to ensure that
the outcomes that are collected in research studies are those that
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matter to patients, carers and health professionals and that the
follow-up times for trials are long enough to capture these. Where
trials are conducted, good practice guidelines must be followed
for their design, implementation and reporting. Further reviews
are being conducted to synthesise evidence regarding the effect
of other dressings on the treatment of pressure ulcers. It would
then be useful to conduct further evidence synthesis (overviews of
reviews, network meta-analyses or both) to aid decision making
about the choice of dressings for pressure ulcers across all dressing
options.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Bale 1997
Methods A multicentre, prospective RCT with 61 participants
Conducted in the UK
Follow-up: 30 d
Participants recruited from 5 centres. Centres not specifically described
Participants Inclusion criteria: aged ≥ 18 years, not pregnant, able to understand and consent to
the trial, no history of poor compliance or previous involvement in the study, Stage II-
III PUs (using the Stirling classification) the largest wound diameter ≤ 11 cm with no
sign of infection (identified as absence of bleeding, friable granulation tissue, offensive
odour and pus secretion)
Exclusion criteria: NR
In the polyurethane foam dressing group at baseline (n = 29):
• median age (years): 74
• gender:female (n = 17), male (n = 12)
• Stage II PU (n = 23), Stage III PU (n = 6)
• location of PUs: sacrum (n = 18), trochanter (n = 1), heel (n = 5), other/not
specifically stated (n = 5)
• wound size (cm2): < 5 cm2 (n = 14); 5 cm2-< 10 cm2 (n = 6); 10 cm2-< 20 cm2 (n
= 4); ≥ 20 cm2 (n = 5)
• amount of exudate: none (n = 8), slight (n = 9), moderate (n = 12)
In the hydrocolloid dressing group at baseline (n = 31):
• median age (years): 73
• gender: female (n = 16), male (n = 15)
• Stage of PU: Stage II (n = 22), Stage III (n = 9)
• location of PUs: sacrum (n = 13), trochanter (n = 1), heel (n = 11), other/not
specifically stated (n = 6)
• wound size (cm2): < 5 cm2 (n = 10); 5 cm2-< 10 cm2 (n = 6); 10 cm2-< 20 cm2 (n
= 9); ≥ 20 cm2 (n = 6)
• amount of exudate: none (n = 10), slight (n = 18), moderate (n = 3)
The study received local research ethics committee approval at each centre and informed
consent was obtained from all participants
Interventions Group A: polyurethane foam dressing (Allevyn Adhesive) until the wound healed, or
for a maximum of 30 d (n = 29)
hydrocolloid dressing (Granuflex) until the wound healed, or for a maximum of 30 d
(n = 31)
Outcomes Primary outcomes: these outcomes are recorded as per the review in relation to primary
and secondary
Incidence of healed PUs (referred to as ”healed wounds“)
Adverse events per participant
Secondary outcomes: NR
Economic outcomes: NR
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Bale 1997 (Continued)
Notes Missingdata/exclusions: of total number of participants recruited (n= 61); ”Sixty patients
were included in the statistical analysis. One patient was excluded who died shortly after
the first dressing application (this was not dressing related).“ (p. 464)
High rate of participant dropout: 18 in the polyurethane foam group, 22 in the hydro-
colloid group
Wounds healed in 12 participants: 7 in the polyurethane foam dressing group, 5 in the
hydrocolloid dressing group
Adverse events: ”There was only one dressing-related adverse incident, where a patient
treated with the polyurethane foam dressing developed a localised skin rash“ (p. 464)
. Mention of ”Damage to the surrounding skin, although rare, was reported in both
groups…“ (p. 466)
Stirling classification system similar to NPUAP/EPUAP/PPPIA classification
Study funded by Smith & Nephew, manufacturer of Allevyn Adhesive
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quotation: ”Patients allocated to one of
two treatment groups sequentially for each
centre, using an open randomisation list.“
Comment: unclear how random sequence
was generated
Allocation concealment (selection bias) Unclear risk Quotation: ”Patients allocated to one of
two treatment groups sequentially for each
centre, using an open randomisation list.“
Comment: not clear how allocation to
group was concealed
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk No direct quotation addressing this aspect
Comment: unclear whether participants
and personnel were blinded to treatment
group
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No direct quotation addressing this aspect
Comment: unclear, blinding of outcome
assessment is not specifically stated
Incomplete outcome data (attrition bias)
All outcomes
High risk Quotations: ”One patient was excluded
who died shortly after the first dressing ap-
plication (this was not dressing related)“
“Forty of the 61 patients enrolled in the
study were withdrawn. The main reasons
for this were that the patients died or were
discharged before their wounds healed.”
Comment: 67% of participants were with-
drawn from the study
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Bale 1997 (Continued)
Selective reporting (reporting bias) Low risk No direct quotation addressing this aspect
Comment: some data not reported, (e.g.
the number of participants who required a
dressing change due to discomfort)
Other bias Low risk No direct quotation addressing this aspect.
Comment: none noted
Bale 1998
Methods A single-centre, prospective, parallel-group RCT with 100 participants
Conducted in the UK
Follow-up: 8 weeks
Participants recruited from the community over 10 month period from 26 April 1993
with the last follow-up visit completed on13 June 1994.Noother specific details provided
Participants Inclusion criteria: judgement by investigator if treatment with study dressings was
appropriate, leg ulcers of any aetiology except those with venous ulceration who were
able to tolerate compression therapy, and those with Stage II and III sore (classified using
an early version of the NPUAP), or other granulating wounds with moderate-high levels
of exudate
Exclusion criteria: pregnant or lactating women, people with pressure sores classified
Stage I or Stage IV (classified using an early version of the NPUAP), wound expected to
heal within 1 week or wound with sloughy or necrotic tissue or grossly infected wound
(although these people could be included in the study after the wound had been debrided
or the infection had been resolved)
If a participant presented with more than one suitable wound, data on the largest wound
was collected during the study period
In the hydrocellular foam dressing group at baseline (n = 50) from combined data of
wound types, PUs, leg ulcers and other
• age (years): mean 76
• gender: female (n = 38), male (n = 12)
• number of PUs in the study: (n = 17, 34%)
• stage of PU (combined data): Stage II (n = 11), Stage III (n = 6)
• size of wound (cm2): (combined) median 4.7, mean 7.5, SD 7.5, range 0.4-30.6
• location of wound: NR
In the hydrocolloid dressing group at baseline (n = 46) from combined data of wound
types, PUs, leg ulcers and other
• age (years) - mean 76
• gender: female (n = 36), male (n = 10)
• number of PUs in the study: (n = 15, 33%)
• stage of PU (combined): Stage II (n = 6), Stage III (n = 9)
• size of wound (cm2) (combined data): median 3.2, mean 4.2, SD 3.9, range 0.5-
21.2
• location of wound: NR
Ethcial approval reported as being obtained, and written consent from participants ob-
tained
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Bale 1998 (Continued)
Interventions Group A: hydrocellular dressing (Allevyn) until the wound healed, or for a maximum
of 8 weeks (n = 50, of which PU n = 17)
Group B: hydrocolloid dressing (Granuflex) until the wound healed, or for a maximum
of 8 weeks (n = 46, of which PU n = 15)
Outcomes Primary outcomes
Adverse events per participant (data not separated by wound type)
Secondary outcomes
Reduction in ulcer size (data not separated by wound type)
Patient satisfaction/acceptability (data not separated by wound type)
Economic outcomes
Cost and incremental cost per event (total costs of study materials and cost effectiveness
per participant)
Notes Missing data/exclusions: ”Four patients have been excluded from the efficacy, perfor-
mance and economic analysis.“
21/49 (43%) of participants in Group B (hydrocolloid dressing) were withdrawn from
the study before completion compared to 10/51 (20%) of participants in Group A (hy-
drocellular foam dressing). However, it is unclear what proportion of those participants
with PUs were withdrawn from the study
Wounds treated in Group A (hydrocellular foam dressing) were significantly larger than
those treated in Group B (hydrocolloid dressing)
Study funded by Smith & Nephew, manufacturer of Allevyn
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quotation: ”...subjects were randomised
in blocks of four to Group A, to receive
the hydrocellular dressing (Allevyn) or to
Group B, to receive the hydrocolloid dress-
ing (Granuflex).“
Comment: no indication of how randomi-
sation was achieved
Allocation concealment (selection bias) Unclear risk Quotation: ”...subjects were randomised
in blocks of four to Group A, to receive
the hydrocellular dressing (Allevyn) or to
Group B, to receive the hydrocolloid dress-
ing (Granuflex).“
Comment: no indication if allocation was
concealed
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quotation: ”All patients in the trial were
treated by research nurses from theWound
Healing Research Unit in accordance with
the study protocol.“
Comment: unclear if participants and per-
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Bale 1998 (Continued)
sonnel were blinded to group allocation
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quotation: ”It must be noted that one of
the problems of collecting subjective data
when it is not a blind assessment is the in-
troduction of unconscious bias.“
Comment: suggests that those assessing the
wounds were not blinded to the interven-
tion
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quotation: ”Four patients have been ex-
cluded from the efficacy, performance and
economic analysis. One patient inGroup A
(hydrocellular foam dressing) had a wound
which was too large. In Group B (hydro-
colloid dressing), two patients were with-
drawn from the study within seven days
and a third died during the study and
the case report form was not recovered.
All other patients recruited (including later
withdrawals) have been incorporated in all
statistical analyses; 43% of patients were
withdrawn after the initial; seven days in
Group B compared to 20% in Group A.
Thus the difference was statistically signif-
icant ( p = 0.012, x 2 = 6.32, df = 1).“
Comment: it appears that all 32 participat-
ing in the PU subgroup were included in
the analysis. Only 4 participants were ex-
cluded for the larger combined group as de-
scribed above
Selective reporting (reporting bias) Unclear risk No direct quotation addressing this aspect
Comment: limited information on which
to judge
Other bias High risk Comment: Subgroup analyses undertaken
in only part of the trial population
Quotation: “Wounds treated in Group A
when the study commenced were signifi-
cantly larger than those treated in Group B
(median 4.7cm2 (p=0.037).”
Comment: dissimilarity of study groups
may be a source of bias, although group
A (hydrocellular foam dressing) were re-
ported as having better outcomes at 56 days
than the hydrocolloid dressing
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Banks 1994a
Methods A randomised controlled comparative study trial with 50 participants in 2 centres
Conducted in the UK
Follow-up: 12 weeks
Participants recruited from a hospital and the community over a 10-month period in
1992. Centres not specifically described
Participants Inclusion criteria: people with Grade 2 or 3 pressure sores (using the Torrance 5-stage
classification system)
Exclusion criteria: people who were terminally ill or unavailable for the full 12-week
trial period, or if the sores were necrotic, infected or over 7 cm in any direction
Limited baseline participant data reported
Combined data reported for age (years): 34, 68% > 75
Combined data reported for gender: female (n = 32, 64%), male (n = 18, 36%)
In the polyurethane foam dressing group at baseline (n = 26)
• wound size (cm2): ≤ 1.0 cm2 (n = 11), ≥ 1.0 cm2-≤ 2.5 cm2 (n = 2), > 2.5 cm2
(n = 6)
In the Control dressing at baseline (n = 24)
• wound size (cm2): ≤ 1.0 cm2 (n = 12), ≥ 1.0 cm2-≤ 2.5 cm2 (n = 2), > 2.5 cm2
(n = 1)
Location of PU reported as percentages for the combined group (n = 100): sacral (n =
53, 52.9%), buttocks (n = 32, 32.4%), trochanter (n = 6, 5.9%), foot (n = 6, 5.9%),
heels (n = 3, 2.9%)
Ethical approval was granted for the study and informed consent obtained from partic-
ipants, next-of-kin of legal guardian
Interventions Group A: polyurethane foam dressing (Lyofoam A) until wound healed, or for a maxi-
mum of 12 weeks (n = 26)
Group B: control dressing (NA) consisting of a layer of knitted viscous multifilament
yarns, which allows exudate through its open structure. This was placed in contact with
the wound surface and secured with a vapour-permeable film dressing (Tegaderm) until
the wound healed, or for a maximum of 12 weeks (n = 24)
Outcomes Primary outcomes
Incidence of healed PUs (i.e., duration of pressure sore healing time in weeks, and
categorised as “completely healed, improved”)
Secondary outcomes
Patient satisfaction (comfort of dressing)
Pain associated with removal of dressing
Economic outcomes: NR
Notes Randomisation resulted in an inequality of initial sore size between the 2 dressing groups
Duration of pressure sites was not known for 14 participants (28%)
Torrence 5-stage pressure sore grading system similar to NPUAP/EPUAP/PPPIA classi-
fication
Missing data/exclusions for 12 withdrawn participants
Funding source not reported
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quotation: “Randomisation was provided
by an independent statistician. Each pa-
tient was allocated via a sealed envelope
containing one of two treatment codes in-
dicating the trial or the control.”
Comment: evidence of appropriate ran-
domisation method
Allocation concealment (selection bias) Low risk Quotation: “Randomisation was provided
by an independent statistician. Each pa-
tient was allocated via a sealed envelope
containing one of two treatment codes in-
dicating the trial or the control.”
Comment: evidence of appropriate alloca-
tion concealment
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quotation: “The weekly patient question-
naires recorded dressing comfort and pain
on its removal of dressings on a scale of 0-
10.”
Quotation: “The weekly nurse question-
naires recorded ease of application and re-
moval of dressings on a scale of 0-10.”
Comment: unclear if participants and per-
sonnel were blinded to group allocation
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Quotation: “The initial wound assessment
and recruitment to the trial was undertaken
by the trial coordinator who also visited the
patients on a weekly basis throughout the
trial period.”
Comment: unclear if those assessing the
wounds were blinded to the intervention
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Quotation: “Followingup the patients each
week for 12 weeks proved difficult, par-
ticularly when patients were transferred to
other wards or discharged”; “In the control
group it is not possible to identify which
aspect of the dressing benefited healing”
Comment: follow-up and comparator data
potentially incomplete
Selective reporting (reporting bias) Unclear risk No direct quotation addressing this aspect
Comment: limited information on which
to judge
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Other bias High risk Quotation: “The patient population may
have influenced wound site, and evaluation
of the patient characteristics show a large
elderly population.”; “In the control group
it is not possible to identify which aspect of
the dressing benefited healing”
Quotation: “Randomisation did result in
an inequality of initial sore size between
the two dressing groups. This could have
had some influence on outcome and future
studies may provide more accurate data if
the initial wound size, and possibly wound
site, were specified.”
Comment: dissimilarity of study groups
may be a source of bias
Meaume 2003
Methods A multi-centre, open, RCT with 38 participants
Conducted in 3 European countries
Follow-up: 8 weeks
Participants recruited from 3 nursing homes in Belgium, France and Italy. No other
specific details provided
Participants Inclusion criteria: participants ≥ 65 years, Stage II PU as per EPUAP which had not
improved in the preceding 4 weeks, a Modified Norton Scale Score ≥ 11, red/yellow
wound according to the Red-Yellow-Black System
Exclusion criteria: underlying disease that may interfere with the treatment of the
PU, food and/or fluid intake score of ≤ 2 on the Modified Norton Scale, allergic/
hypersensitivity to any material in the dressings, a wound larger than 11 cm x 11 cm, a
wound with black necrotic tissue or clinical signs of local infection at baseline
In the silicone foam dressing group at baseline (n = 18):
• age (years): mean 83.8, range 74.9-95.1
• gender: female (n = 16), male (n = 2)
• location of PUs: heel (n = 5), foot (n = 2), leg (n = 1), sacrum (n = 3), back/other
(n = 3) and ischium (n = 2)
• appearance of ulcer: granulation ( n = 13), epithelialisation (n = 10), exudate (n=
13), maceration (n = 6)
• duration of ulcer (weeks): mean 8.3, range 1-24
• dressing changes prior to enrolment into the study (per week): 3.6, range 1-7
• history of surgical intervention (n = 7)
• wound size (cm2): mean 4.9, range 0.7-25.3
• Use of other PU prevention devices: pressure relieving mattress (n = 11) and other
devices such as position changes or pressure relieving boots (n = 3)
In the hydropolymer foam dressing group at baseline (n = 20):
• age (years): mean 82.5, range 66.4-91.9
• gender: female (n = 16), male (n = 4)
• location of PUs: heel (n = 4), foot (n = 2), leg (n = 4), sacrum (n = 6), back/other
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(n = 2), ischium (n = 1) and elbow (n = 1)
• appearance of ulcer: granulation (n =19), epithelialisation (n = 12), exudate (n=
17), maceration (n = 2), leakage (n = 1)
• duration of ulcer (weeks): mean 13, range 1-52
• dressing changes prior to enrolment into the study (per week): 3.5, range 1-7
• history of surgical intervention (n = 5)
• wound size (cm2): mean 4.9, range 0.7-25.3
• Use of other PU prevention devices: pressure relieving mattress (n = 16) and other
devices such as position changes or pressure relieving boots (n = 16)
Study performed in accordance with ethical principals outlined in the Declaration of
Helsinki and informed, written consent obtained from all participants
Interventions GroupA: silicone foam dressing (Mepilex Border byMolnlycke) until the wound healed,
or for a maximum of 8 weeks (n = 18)
Group B: hydropolymer foam dressing (Tielle by Johnson & Johnson) until the wound
healed, or for a maximum of 8 weeks (n = 20)
Outcomes Primary outcomes
Incidence of healed PUs
Adverse events
Secondary outcomes
Reduction in ulcer size
Economic outcomes: NR
Notes Only 1 PU per participant
Adverse events per participant
• Silicone foam dressing group: 4 participants reported adverse events; three were
unrelated to the study dressing (1 participant in poor general health died, one suffered
a hip fracture, and one has a PU that deteriorated to a Stage IV PU. 1 participant had
hypergranulation tissue formation, which could be classified as an adverse device event
• Hydropolymer dressing group: 6 participants had adverse events; four were due to
the device (hypergranulation tissue formation, new wounds, redness and irritation, 1
participant died of broncho-pneumonia, and 1 participant developed symptoms of
heart disease
Funding source: NR
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quotation: “Participants were randomly
assigned to one of the two treatment op-
tions by a predetermined computer-gener-
ate randomisation list stratified by study
centre, and the block size was unknown
to the investigators. Each centre received
numbered, sealed envelopes to be opened
in consecutive order.”
Comment: evidence of appropriate ran-
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domisation method
Allocation concealment (selection bias) Low risk Quotation: ”Participants were randomly
assigned to one of the two treatment op-
tions by a predetermined computer-gener-
ate randomisation list stratified by study
centre, and the block size was unknown
to the investigators. Each centre received
numbered, sealed envelopes to be opened
in consecutive order.”
Comment: evidence of appropriate ran-
domisation method
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quotation: “The study was not blinded be-
cause dressing differences make blinding
difficult to achieve.”
Comment: participants andpersonnel were
not blinded to group allocation
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quotation: “The study was not blinded be-
cause dressing differences make blinding
difficult to achieve.”
Comment: outcome assessment not
blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk No direct quotation addressing this aspect
Comment: data appear to be presented for
all participants
Selective reporting (reporting bias) Low risk Quotation: “The results of this exploratory
study indicate that the soft silicone dress-
ing is superior to dressings using traditional
adhesive technologies. These findings need
to be confirmed in other controlled stud-
ies”
Comment: acknowledged to be an ex-
ploratory study. Data appear to be pre-
sented for all participants
Other bias Low risk Quotation: “Patients were excluded from
this study if they suffered from an underly-
ing disease that, according to the investiga-
tor, might possibly interfere with the treat-
ment of the pressure ulcer”
Comment: limited information on which
to judge
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Methods A multicentre prospective, RCT with 36 participants
Conducted in the USA
Follow-up: 4 weeks
Participants recruited from 3 hospital inpatient wards, 1 hospital-based outpatients’
clinic, 1 long-term residential care centre and a community-based wound clinic in the
USA between November 2005 and March 2007
Participants Inclusion criteria: participants had to be ≥ 18 years of age, either gender, not pregnant
or using contraception, and have a Stage II PU as per the NPUAP classification system
with slight to moderate levels of exudate. If the participant had more than one eligible
wound, the largest was selected for the study
Exclusion criteria: people with a history of poor compliance, presence of clinical infec-
tion in the wounds, presence of Stage I, III or IV PU, previous participation in the study
In the polyurethane foam dressing group at baseline (n = 20):
• age (years): median 72.5 mean 74, SD 14.3
• gender: female (n = 7), male (n = 13)
• location of PUs: hips/buttocks (n = 7), sacrum (n = 8), upper leg (n = 1), ankle/
foot (n = 4)
• duration of ulcer (weeks): mean 8.3, range 1-24
• wound size (cm2): mean 5.6, median 1.8, SD 11.3
In the saline-soaked gauze dressing group at baseline (n = 16):
• age (years): median 73.3 mean 71.5, SD 12.4
• gender: female (n = 7), male (n = 9)
• location of PUs: hips/buttocks (n = 7), sacrum (n = 7), ankle/foot (n = 1), lower
leg (n = 1)
• duration of ulcer (weeks): mean 8.3, range 1-24
• wound size (cm2): mean 6.2, median 1.4 SD 7.2
Ethics approval was obtained from each of the 5 participating centres and participants,
their legal representative, guardian or care-giver gave informed written consent
Interventions Group A: self-adhesive polyurethane foam dressing (Allevyn Thin, Smith & Nephew)
until the wound healed, or for a maximum of 4 weeks (n = 20)
Group B: saline-soaked gauze until the wound healed, or for a maximum of 4 weeks (n
= 16)
Outcomes Primary outcomes
Incidence of healed PUs
Reduction in ulcer size
Secondary outcomes: NR
Economic outcomes
Cost and incremental cost per event (cost of materials per participant, per ulcer healed
and per ulcer-free day)
Notes Missing data/exclusions: 2 participants were excluded from the costing analyses
Reason for withdrawals: “Nine patients were withdrawn from the study - six in the foam
group (three died, one developed a wound infection, one developed an abscess unrelated
to the study wound, and one became ineligible for other reasons) and three in the gauze
group (two died and one asked to be discharged form hospital).” (p. 53)
Wound preparation (cleaning and drying the wound) was not standardised and each
participant was treated according to the normal practice of each study centre
49Foam dressings for treating pressure ulcers (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Payne 2009 (Continued)
Study authors acknowledged a measure of participant-assessed quality of life should have
been included in the study to ensure that results did not impact on patient quality of life
Study funded by Smith & Nephew
Authors Posnett, Sharma and Hartwell were employees of Smith & Nephew at the time
of the study
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quotation: “Consenting patients were as-
signed a sequential patient number at each
study centre. A randomisation schedule de-
termined treatment allocation to either self-
adhesive polyurethane foam dressing…or
saline-soaked gauze.”
Comment: not clear how randomisation
schedule was devised or implemented
Allocation concealment (selection bias) High risk Quotation: “Consenting patients were as-
signed a sequential patient number at each
study cent er. A randomisation schedule de-
termined treatment allocation to either self-
adhesive polyurethane foam dressing…or
saline-soaked gauze.”
Comment: not clear how allocation was
concealed
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quotation: “Study participants were not
blinded.”
Quotation: “In both study groups, dress-
ing change frequencywas determined at the
discretion of the clinical investigator.”
Comment: participants andpersonnel were
not blinded to group allocation
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quotation: “In both study groups, dress-
ing change frequencywas determined at the
discretion of the clinical investigator.”
Quotation: “Details of wound healing and
dressing changes at each assessment were
recorded by the study investigator directly
to a case report from (CRF)
Comment: outcome assessment not
blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quotation: “Two patients in the foam
group had no information recorded on
dressing changes between weekly assess-
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ment. These patients were included in the
full data analysis set, but because it is
likely these patients had additional dressing
changes that were not recorded, including
costs for these patients, may have led to an
underestimation of average treatment costs
for patients in the foam group. For this rea-
son these patients were excluded from the
costing analysis.”
Comment: adequate evidence to assume
low risk judgement
Selective reporting (reporting bias) Unclear risk No direct quotation addressing this aspect
Comment: limited information on which
to judge
Other bias Low risk Quotations: “There was no evidence of a
difference in the time to wound closure be-
tween the two treatment groups (P=0.817)
.”; “The study was not powered to detect a
difference in time to healing and although
a difference favouring the foam group was
observed, this difference was not statisti-
cally significant at the 5% level”
Comment: limited information on which
to judge
Seeley 1999
Methods A multi-centre, prospective, randomised, stratified, parallel-group study with 40 partic-
ipants
Conducted in the USA
Follow-up: 8 weeks
Participants recruited over 17 months from “several” long-term care facilities and from
outpatients from diabetic foot and wound centre. No other details provided
Participants Inclusion criteria: either sex, > 18 years with ≥ 1 Stage II or III PU (as per an early
version of the NPUAP classification system known as the Agency for Health Care Policy
and Research system), were recruited sequentially into the study. If the participant had
more than one PU, the largest ulcer that met the inclusion criteria was selected as the
study ulcer
Exclusion criteria: If the ulcer was smaller than 1 cm2 or larger then 50 cm2 or if the
ulcer was considered to be clinically infected, people with uncontrolled diabetes or a
known history of poor compliance with medical treatment
In the hydrocellular foam dressing group at baseline (n = 20):
• age (years) - mean 75.7, SD 18.6
• gender: female (n = 11), male (n = 9)
• stage of PU: Stage II (n = 3), Stage III (n = 17)
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• location of PUs: sacrum or coccyx (n = 4), heel (n = 7), foot or ankle (n = 3),
trochanter (n = 1), ischium (n = 1), thigh (n = 2), buttocks (n = 1) and other (n = 1)
• appearance of ulcer: sloughy (n = 5), unhealthy granulation (n = 5), healthy
granulation (n = 9), not recorded (n = 1)
• condition of skin and ulcer: healthy (n = 4), inflamed (n = 6), macerated (n = 5),
inflamed and macerated (n =1), other (n = 4)
• wound pain: yes (n = 10), no (n = 9), unassessable (n = 1)
• duration of ulcer (weeks): mean 11.8, SD 7.4, median 9
• wound size (cm2): mean 6.84, SD 8.19
In the hydrocolloid dressing group at baseline (n = 19):
• age (years): mean 76.7, SD 19.5
• gender: female (n = 10), male (n = 9)
• stage of PU: Stage II (n = 2), Stage III (n = 17)
• location of PUs: sacrum or coccyx (n = 5), heel (n = 3), foot or ankle (n = 4),
trochanter (n = 1), ischium (n = 1), thigh (n = 1), buttocks (n = 2) and other (n = 2)
• appearance of ulcer: sloughy (n = 3), unhealthy granulation (n = 4), healthy
granulation (n = 10), sloughy and granulation (n = 1), not recorded (n = 1)
• condition of skin and ulcer: healthy (n = 11), inflamed (n = 5), macerated (n = 1),
inflamed and macerated (n = 0), other (n = 2)
• wound pain: yes (n = 6), no (n = 8), unassessable (n = 5)
• duration of ulcer (weeks): mean 23.1, SD 38.9, median 10
• wound size (cm2): mean 4.61, SD 5.56
Ethics approval was obtained and participant, or their authorised representative gave
informed written consent
Interventions Group A: hydrocellular dressing (Allevyn Hydorcellular, Smith & Nephew) until the
wound healed, the participant was withdrawn, or for a maximum of 8 weeks (n = 20)
Group B: hydrocolloid dressing (Duoderm CGF Border Dressing, ConvaTec) until the
wound healed, the participant was withdrawn, or for a maximum of 8 weeks (n = 19)
Outcomes Primary outcomes
Incidence of healed PUs
Adverse events per participant
Secondary outcomes
Pain associated with a PU or dressing removal, or both
Economic outcomes: NR
Notes Only 1 PU per participant
Missing data/exclusions - “Forty patients were recruited into the study. One patient in
the hydrocolloid group died shortly after enrolment and was excluded from the statistical
analysis. The death was not related to the study dressing.” (p. 41)
Funding source not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quotation: “The randomisation was strat-
ified into three groups (small, medium,
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large) according to the initial ulcer size (1
to 10 cm2, 10.1 to 20 cm2, and 20.1 to 50
cm2, respectively). Within
each strata, patientswere randomised to the
hydrocellular or hydrocolloid dressing us-
ing a computer generated list.”
Comment: evidence of appropriate ran-
domisation method
Allocation concealment (selection bias) Low risk Quotation: “The frequency of dressing
changes was dictated by the individual
wound’s condition and was left to the
judgement of the clinical investigator.”
Quotation: “The time needed to change
each of the dressings at the weekly assess-
ments was recorded in minutes. The dress-
ing wear times were calculated from data
recorded in the dressing
diaries.”
Comment: study group allocation not con-
cealed
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quotation: “The frequency of dressing
changes was dictated by the individual
wound’s condition and was left to the
judgement of the clinical investigator.”
Quotation: “The time needed to change
each of the dressings at the weekly assess-
ments was recorded in minutes. The dress-
ing wear times were calculated from data
recorded in the dressing diaries.”
Comment: participants andpersonnel were
not blinded to group allocation
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quotation: “The frequency of dressing
changes was dictated by the individual
wound’s condition and was left to the
judgement of the clinical investigator.”
Comment: outcome assessment not
blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quotation: “Forty patients were recruited
into the study. One patient in the hydro-
colloid group shortly after enrolment and
was excluded from the statistical analysis.
This death was not related
to the study dressing.”
Comment: adequate evidence to assume
low risk judgement
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Selective reporting (reporting bias) Low risk Quotation: “The study ulcer was evaluated,
traced and photographed at baseline (week
0) and thereafter at weeks 1 to 8.”
Quotation: “The mean percentage reduc-
tions in ulcer area from the patient’s initial
weeks to final week were 50% and 52% for
the hydrocellular and hydrocolloid groups,
respectively (P=0.31). ”
Comment: although the study ulcer was
accessed and measured each week, results
for ulcer area reported as amean percentage
rather than in cm2
Other bias Unclear risk Quotation: “It therefore can be argued that
the wear time generated in this study is not
a true reflection of the maximum average
wear time for either dressing”
Comment: limited information on which
to judge
Sopata 2002
Methods A single-centre prospective, RCT with 34 participants with advanced cancer
Conducted in Poland
Follow-up: 8 weeks
Participants recruited over 3 years from January 1996-January 1999 in a palliative care
department
Participants Inclusion criteria: advanced cancer and a life expectancy of > 8 weeks, Grade II or III
PUs (using the Torrance 5-stage classification system)
Exclusion criteria: poor general condition, with low levels of haemoglobin and albumin
and use of drugs such as corticosteroids that could affect wound healing
In the polyurethane foam dressing group at baseline (n = 17, with 18 ulcers):
• age (years): mean 58.5, SD 16.92
• gender: female (n = 10), male (n = 7)
• stage of PU: Stage/Grade II (n = 6), Stage/Grade III (n = 12)
• duration of ulcer (weeks): mean 2.46, SD 0.24
• wound size (cm2): mean 11.04, SD 11.65
• location of PUs: NR
In the hydrogel dressing group at baseline (n = 17, with 20 ulcers):
• age (years): mean 58.7 SD 14.11
• gender: female (n = 8), male (n = 9)
• stage of PU: Stage/Grade II (n = 6), Stage/Grade III (n = 14)
• duration of ulcer (weeks): mean 2.45, SD 1.60
• wound size (cm2): mean 8.28, SD 13.90
• location of PUs: not reported
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Interventions Group A: polyurethane dressing (Lyofoam) until the wound healed, or for a maximum
of 8 weeks (n = 17, with 18 ulcers)
Group B: hydrogel dressing (Aquagel) until the wound healed, or for a maximum of 8
weeks (n = 17, with 20 ulcers)
Outcomes Primary outcomes
Note: primary outcomes reported in this study were different to a priori criteria reported
in the review protocol
Incidence of healed PUs
Time to complete healing (in days)
Adverse events per participant
Secondary outcomes
Reduction in ulcer size
Economic outcomes: NR
Notes A primary outcome of this review was to measure the incidence of healed PUs with
respect to the unit of analysis being the proportion of participants in whom a PU healed.
There is limited information to extrapolate this information from the analysis presented
Ethical approval for the study and informed consent for participants NR
Funding source NR
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quotation: “Patients were randomly allo-
cated, using a computer number system, to
treatment with either Lyofoam or Aquagel.
”
Comment: not clear how randomisation
schedule was devised or implemented
Allocation concealment (selection bias) Unclear risk Quotation: “Patients were randomly allo-
cated, using a computer number system, to
treatment with either Lyofoam or Aquagel.
”
Comment: not clear if allocation was con-
cealed
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quotation: “All patients were treated by the
main researcher (M. Sopata) or by one of
two departmental nurses.”
Comment: not clear if some participants
and personnel were blinded to group allo-
cation
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quotation: “All patients were treated by the
main researcher (M. Sopata) or by one of
two departmental nurses.”
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Comment: outcome assessment not
blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quotation: “In the Lyofoam group, six
(100%) Grade II and nine (75%) Grade II
ulcers healed. Three Grade III ulcers im-
proved although two of these belonged to
patients who died before the end of the
study and one did not heal. In the Aqu-
cel group, six (100%) Grade II and nine
64%)Grade III ulcers healed. Four patients
had four wounds that improved (29%) but,
again, these wounds belonged to three pa-
tients who does before the end of the study
and one did not heal. The treatment failed
in one ulcer.”
Comment: ITT analysis assumed suggest-
ing complete reporting of outcome data
Selective reporting (reporting bias) Low risk No direct quotation addressing this aspect
Comment: outcome measures reported in
methods section were reported in the re-
sults section
Other bias Low risk No direct quotation addressing this aspect
Comment: none noted
Souliotis 2016
Methods A RCT of 100 people with full thickness PUs treated at home
Greece
Participants recruited from the community and treated in their homes
Follow-up until complete healing
Participants Inclusion criteria: Stage III or IV PU using the EPUAP classification system)
Exclusion criteria:
• < 18 years old
• end stage chronic heart disease
• renal disease
• chronic obstructive pulmonary disease
• dependent diabetes
• cancer
• serious immunodeficiency
• severe systematic infection
• previous ulcer treatment with a different method
In the moist wound healing group (n = 47)
• included foam dressings, silver foam dressings, silver-sulfadiazine dressings and
ibuprofen-releasing foam dressings
• age (years): mean 75.5, SD 8.6
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• gender: female (n = 20), male (n = 27)
• location of PUs: coccyx (n = 18), buttocks (n = 8), trochanters (n = 12), heels (n =
7), other (n = 2)
• initial ulcer surface in cm2: mean 43.5, SD 30.7
• total number treatment days until healing: 4278
• average number treatment days until healing: mean 85.6, SD 52.1
• total dressing change until healing: 2475
• average dressing change until healing: mean 49.5, SD 29.6
• local infection in 12 cases x 8 participants - 4 showing 1 case of infection during
treatment and 4 showing 2 cases
In the plain gauze group (n = 48)
• included plain sterile gauzes or saline-moistened gauzes held in place with
adhesive tape
• age (years): mean 77.2, SD 8.02
• gender: female (n = 23), male (n- 25)
• location of PUs: coccyx (n = 16), buttocks (n = 6), trochanters (n = 13), heels (n =
10), other (n = 3)
• initial ulcer surface in cm2: mean 41.52, SD 29.4
• total number treatment days until healing: 6070
• average number treatment days until healing: mean 121.4, SD 52.2
• total dressing change until healing: 11,130
• average dressing change until healing: mean 222.6, SD 101.9
• local infection in 21 cases x 14 participants - 9 showing 1 case of infection during
treatment and 6 showing 2 cases
Participants were fully informed about the aim of the study and that participation was
optional and that they could drop out of the study. All participants signed an informed
consent form, and in those cases where they were unable to do so, a designated person
signed for them. Participants’ personal data were codified to ensure anonymity and
confidentiality
Interventions Group A: moist wound dressings (foam dressing with anti-microbial and analgesic vari-
ations) until the wound healed, with no time limit (participants with pressure sores, n =
47)
Group B: plain gauze (including gauze soaked in saline) until the wound healed, with
no time limit (participants with pressure sores, n = 48)
Outcomes Primary outcomes
Time to complete healing (in days)
Adverse events per participant (local wound infection)
Secondary outcomes: NR
Economic outcomes
Cost and incremental cost per event (cost of clinical materials per participant, daily wages
and cost of healthcare professionals per home visit)
Notes Only 1 ulcer per person
Data collection and ulcer measurements took place once a month until complete healing
Costs of dressings and materials informed by the (Greek) Committee forHealth Supplies
and the average purchase prices paid by public hospitals. Costs per home visit came from
official sources regarding public servants’ monthly wages and labour costs
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Souliotis 2016 (Continued)
Funding source NR
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quotation: “The allocation of the subjects
in the group of moist wound dressings and
the gauze group was randomised by using
sealed opaque envelopes.”
Comment: not clear how randomisation
schedule was devised
Allocation concealment (selection bias) Low risk Quotation: “The allocation of the subjects
in the group of moist wound dressings and
the gauze group was randomised by using
sealed opaque envelopes.”
Comment: evidence of appropriate ran-
domisation method
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No direct quote addressing this aspect
Comment: participants and personnel not
blinded to group allocation
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quotation: “Home treatment was per-
formed by healthcare professionals accord-
ing to the patients’ needs and the ulcer
treatment protocols applied by each health-
care service. For the ulcer surface measur-
ing, sterile transparent graded films were
used.”
Comment: outcome assessment not
blinded
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Quotation: “One patient of the group un-
der treatment with plain gauze and two
from the group under treatmentwithmoist
wound healing dressings had to be with-
drawn from the study. One patient from
each group died during the course of the
study. The data of the patients who did not
complete the study were not included in
the data analysis.”
Comment: a per-protocol approach which
potentially contributed to bias
Selective reporting (reporting bias) Unclear risk No direct quotation addressing this aspect
Comment: limited information on which
to judge
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Souliotis 2016 (Continued)
Other bias Low risk No direct quotation addressing this aspect
Comment: none noted
Thomas 1997
Methods A 2-centred, open, randomised, controlled, comparative study with 199 participants
(PUs n = 99, leg ulcers n = 100)
Place of study NR. Assumed to be UK (Wales) where authors are located
Follow-up: 6 weeks
Participants recruited from the community. No other details provided
Participants Inclusion criteria: Grade 2 or 3 PUs (using the Stirling Classification), had an ulcer less
then 10 mm deep and a maximum diameter of 8 cm (to allow a single dressing to cover
the entire ulcer)
Exclusion criteria: participants < 16 years, were known to have a history or poor compli-
ance with medical treatment, had insulin-dependent diabetes, were considered unlikely
to survive the period of the study, had previously demonstrated adverse reactions to one
of the dressings being tested, had wounds that were clinically infected
In the hydropolymer foam dressing group at baseline (n = 50):
• age (years): mean 80.1, SD 10.2
• gender: female (n = 35), male (n = 15)
• stage of PU: stage 2 (n = 27), stage 3 (n = 23)
• location of PUs: heel (n = 23), buttock (n = 6), sacrum (n = 10), hip (n = 2) and
other (n = 9)
• duration of wound (months): < 1 month (n = 8), 1-3 months (n = 21), > 3
months (n = 20), missing data (n = 1)
In the hydrocolloid dressing group at baseline (n = 49):
• age (years): mean 78.6 SD, 14.3
• gender: female (n = 33), male (n = 16)
• stage of PU: Grade 2 (n = 30), Grade 3 (n = 19)
• location of PUs: heel (n = 25), buttock (n = 2), sacrum (n = 6), hip (n = 4) and
other (n = 12)
• duration of wound (months): < 1 month (n = 9), 1-3 months (n = 18), > 3
months (n = 21), missing data (n = 1)
Ethics committee approval obtained. Participants provided written informed consent
prior to randomisation and collection of demographic data
Interventions Group A: hydropolymer foam dressing (Tielle) until the wound healed, or for a maxi-
mum of 6 weeks (participants with PUs, n = 50)
Group B: hydrocolloid dressing (Granuflex) until the wound healed, or for a maximum
of 6 weeks (participants with PUs, n = 49)
Outcomes Primary outcomes
Incidence of healed PUs (categorised as “totally healed, improved, not healed, un-
changed”)
Adverse events per participant (categorised as ulcer “deteriorated”)
Secondary outcomes
Reduction in ulcer size (data not separated by wound type)
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Thomas 1997 (Continued)
Economic outcomes: NR
Notes Only one ulcer per person
Participants with PU were cared for using appropriate pressure-relieving devices
Adverse events linked to dressings (most frequently related to the adhesive nature of the
dressings causing trauma)
Funding source NR
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quotation: “...patients who…gave in-
formed consent in writing were allocated to
the two treatment groups on a randomised
basis, using a system of sealed envelopes.”
Comment: method of randomisation not
described. Not clear if envelopes were se-
quentially numbered to ensure random se-
quence was maintained
Allocation concealment (selection bias) High risk Quotation: “An open, randomised, con-
trolled, two-centred, comparative study…”
Comment: an open study. Group alloca-
tion not concealed
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Quotation: “An open, randomised, con-
trolled, two-centred, comparative study…”
Comment: an open study. Participants and
personnel not blinded to group allocation
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quotation: “An open, randomised, con-
trolled, two-centred, comparative study…”
Quotation: “To ensure accurate data collec-
tion, all dressing changes were undertaken
by dedicated research nurses…”
Comment: outcome assessment not
blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quotation: “Details of all adverse events
were documented. If a patient was with-
drawn from the study, the reason was
recorded and a decisionmade as to whether
this was the result of an adverse reaction
related to the use of the dressing or a non-
dressing related event.”
Comment: data reported for all partici-
pants randomised
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Thomas 1997 (Continued)
Selective reporting (reporting bias) Unclear risk No direct quotation addressing this aspect
Comment: limited information on which
to judge
Other bias Low risk No direct quotation addressing this aspect
Comment: none noted
ITT: intention-to-treat; NR: not reported; PU: pressure ulcer; RCT: randomised controlled trial
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Ashby 2012 Although the study was an RCT, it had a mixed-dressing control arm with foam dressings being 1 of 3
dressing options based on health professional and participant choice rather than randomisation
Avanzi 2000 Paper incomplete and review authors unable to access it
Banks 1994b PU classification system not stated. Review authors unable to access original data
Banks 1994c PU classification system not stated. Review authors unable to access original data
Banks 1997 PU classification system not stated. Review authors unable to access original data
Brown-Etris 1996 The intervention dressing (Transorbant) has dry hydrogel and foam layers. We excluded this study as the
hydrogel layer was closest to the skin, and the foam was an outer layer that provided cushioning
Diehm 2005 Not a RCT or cluster-RCT
Münter 2006 No subgroup analysis of participants with PUs. Review authors unable to access original data
Oleske 1986 Not a RCT or cluster-RCT
Palao i Domenech 2008 No subgroup analysis of participants with PUs. Unable to contact study authors
Parish 2008 Not a RCT or cluster-RCT
Piatkowski 2012 Administered foam dressing to participants on both trial arms
Reynolds 2004 PU classification system not stated. Unable to contact study author
Romanelli 2009 Subanalysis of larger study by Palao i Domenech 2008. Does not include participants with PUs
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(Continued)
Wagstaff 2014 While this trial compared two foams for the treatment of PUs, their application occurred as a component
of negative pressure wound therapy following surgical debridement rather than as a wound dressing
Zimny 2003 Participants had neuropathic foot ulcers, not PUs.
PU: pressure ulcer; RCT: randomised controlled trial
Characteristics of ongoing studies [ordered by study ID]
ISRCTN57842461
Trial name or title A multi-centre, randomised, clinical trial comparing adhesive polyurethane foam dressing and adhesive hy-
drocolloid dressing in patients with grade II pressure ulcers in primary care and nursing homes
Methods RCT
Participants Planning to recruit 820 participants from primary health care and home care centres
Interventions Adhesive polyurethane foam
Outcomes Percentage of wounds healed after 8 weeks
Starting date ISRCTN record shows starting date of 30 September 2012 and end date of 30 September 2015
Contact information M Guillén-Solà: mguillen@ibsalut.caib.es
Notes Country: Spain
RCT: randomised controlled trial
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D A T A A N D A N A L Y S E S
Comparison 1. Foam dressing compared with other foam dressing
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Incidence of healing, short-term
follow-up
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2 Adverse events, short-term
follow-up
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
Comparison 2. Foam dressings compared with hydrocolloid dressing
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Incidence of healing, short-term
follow-up
3 198 Risk Ratio (M-H, Fixed, 95% CI) 0.85 [0.54, 1.34]
2 Adverse events, short-term
follow-up
3 198 Risk Ratio (M-H, Fixed, 95% CI) 0.88 [0.37, 2.11]
3 Pain, short-term follow-up 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
Comparison 3. Foam dressing compared with hydrogel dressing
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Incidence of healing, short-term
follow-up
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2 Time to complete healing (in
days), short-term follow-up
1 34 Mean Difference (IV, Fixed, 95% CI) 5.67 [-4.03, 15.37]
3 Adverse event, short-term
follow-up
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
4 Reduction in ulcer size per day 1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
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Comparison 4. Foam dressings compared with basic wound contact dressings
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Incidence of healing 2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 Short-term follow-up 1 36 Risk Ratio (M-H, Fixed, 95% CI) 1.33 [0.62, 2.88]
1.2 Medium-term follow-up 1 50 Risk Ratio (M-H, Fixed, 95% CI) 1.17 [0.79, 1.72]
2 Time to complete healing (in
days), medium-term follow-up
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
3 Adverse events, medium-term
follow-up
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
Analysis 1.1. Comparison 1 Foam dressing compared with other foam dressing, Outcome 1 Incidence of
healing, short-term follow-up.
Review: Foam dressings for treating pressure ulcers
Comparison: 1 Foam dressing compared with other foam dressing
Outcome: 1 Incidence of healing, short-term follow-up
Study or subgroup Silicone foam Hydropolymer foam Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Meaume 2003 8/18 10/20 0.89 [ 0.45, 1.75 ]
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours other foam Favours silicone foam
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Analysis 1.2. Comparison 1 Foam dressing compared with other foam dressing, Outcome 2 Adverse events,
short-term follow-up.
Review: Foam dressings for treating pressure ulcers
Comparison: 1 Foam dressing compared with other foam dressing
Outcome: 2 Adverse events, short-term follow-up
Study or subgroup Silicone foam Hydropolymer foam Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Meaume 2003 1/18 3/20 0.37 [ 0.04, 3.25 ]
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours silicone foam Favours other foam
Analysis 2.1. Comparison 2 Foam dressings compared with hydrocolloid dressing, Outcome 1 Incidence of
healing, short-term follow-up.
Review: Foam dressings for treating pressure ulcers
Comparison: 2 Foam dressings compared with hydrocolloid dressing
Outcome: 1 Incidence of healing, short-term follow-up
Study or subgroup Foam dressings
Hydrocolloid
dressings Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bale 1997 7/29 5/31 16.6 % 1.50 [ 0.53, 4.19 ]
Seeley 1999 8/20 8/19 28.1 % 0.95 [ 0.45, 2.02 ]
Thomas 1997 10/50 16/49 55.3 % 0.61 [ 0.31, 1.21 ]
Total (95% CI) 99 99 100.0 % 0.85 [ 0.54, 1.34 ]
Total events: 25 (Foam dressings), 29 (Hydrocolloid dressings)
Heterogeneity: Chi2 = 2.12, df = 2 (P = 0.35); I2 =6%
Test for overall effect: Z = 0.69 (P = 0.49)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours hydrocolloid Favours foam
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Analysis 2.2. Comparison 2 Foam dressings compared with hydrocolloid dressing, Outcome 2 Adverse
events, short-term follow-up.
Review: Foam dressings for treating pressure ulcers
Comparison: 2 Foam dressings compared with hydrocolloid dressing
Outcome: 2 Adverse events, short-term follow-up
Study or subgroup Foam Hydrocolloid Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bale 1997 1/29 0/31 5.0 % 3.20 [ 0.14, 75.55 ]
Seeley 1999 2/20 2/19 21.4 % 0.95 [ 0.15, 6.08 ]
Thomas 1997 5/50 7/49 73.6 % 0.70 [ 0.24, 2.06 ]
Total (95% CI) 99 99 100.0 % 0.88 [ 0.37, 2.11 ]
Total events: 8 (Foam), 9 (Hydrocolloid)
Heterogeneity: Chi2 = 0.82, df = 2 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 0.29 (P = 0.77)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours foam Favours hydrocolloid
Analysis 2.3. Comparison 2 Foam dressings compared with hydrocolloid dressing, Outcome 3 Pain, short-
term follow-up.
Review: Foam dressings for treating pressure ulcers
Comparison: 2 Foam dressings compared with hydrocolloid dressing
Outcome: 3 Pain, short-term follow-up
Study or subgroup Foam Hydrocolloid
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Seeley 1999 20 0.15 (0.8) 19 0.47 (0.9) -0.32 [ -0.86, 0.22 ]
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Favours foam Favours hydrocolloid
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Analysis 3.1. Comparison 3 Foam dressing compared with hydrogel dressing, Outcome 1 Incidence of
healing, short-term follow-up.
Review: Foam dressings for treating pressure ulcers
Comparison: 3 Foam dressing compared with hydrogel dressing
Outcome: 1 Incidence of healing, short-term follow-up
Study or subgroup Foam dressing hydrogel dressing Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Sopata 2002 15/17 15/17 1.00 [ 0.78, 1.28 ]
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours foam Favours hydrogel
Analysis 3.2. Comparison 3 Foam dressing compared with hydrogel dressing, Outcome 2 Time to complete
healing (in days), short-term follow-up.
Review: Foam dressings for treating pressure ulcers
Comparison: 3 Foam dressing compared with hydrogel dressing
Outcome: 2 Time to complete healing (in days), short-term follow-up
Study or subgroup Foam dressing Hydrogel dressing
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Sopata 2002 17 25.77 (14.15) 17 20.1 (14.7) 100.0 % 5.67 [ -4.03, 15.37 ]
Total (95% CI) 17 17 100.0 % 5.67 [ -4.03, 15.37 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.15 (P = 0.25)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours foam Favours hydrogel
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Analysis 3.3. Comparison 3 Foam dressing compared with hydrogel dressing, Outcome 3 Adverse event,
short-term follow-up.
Review: Foam dressings for treating pressure ulcers
Comparison: 3 Foam dressing compared with hydrogel dressing
Outcome: 3 Adverse event, short-term follow-up
Study or subgroup Foam dressing hydrogel dressing Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Sopata 2002 0/17 1/17 0.33 [ 0.01, 7.65 ]
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours foam Favours hydrogel
Analysis 3.4. Comparison 3 Foam dressing compared with hydrogel dressing, Outcome 4 Reduction in ulcer
size per day.
Review: Foam dressings for treating pressure ulcers
Comparison: 3 Foam dressing compared with hydrogel dressing
Outcome: 4 Reduction in ulcer size per day
Study or subgroup Foam dressing Hydrogel dressing
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Sopata 2002 15 0.75 (0.85) 15 0.45 (0.28) 0.30 [ -0.15, 0.75 ]
Test for subgroup differences: Not applicable
-1 -0.5 0 0.5 1
Favours foam Favours hydrogel
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Analysis 4.1. Comparison 4 Foam dressings compared with basic wound contact dressings, Outcome 1
Incidence of healing.
Review: Foam dressings for treating pressure ulcers
Comparison: 4 Foam dressings compared with basic wound contact dressings
Outcome: 1 Incidence of healing
Study or subgroup Foam dressing Basic dressings Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Short-term follow-up
Payne 2009 10/20 6/16 100.0 % 1.33 [ 0.62, 2.88 ]
Subtotal (95% CI) 20 16 100.0 % 1.33 [ 0.62, 2.88 ]
Total events: 10 (Foam dressing), 6 (Basic dressings)
Heterogeneity: not applicable
Test for overall effect: Z = 0.73 (P = 0.46)
2 Medium-term follow-up
Banks 1994a 19/26 15/24 100.0 % 1.17 [ 0.79, 1.72 ]
Subtotal (95% CI) 26 24 100.0 % 1.17 [ 0.79, 1.72 ]
Total events: 19 (Foam dressing), 15 (Basic dressings)
Heterogeneity: not applicable
Test for overall effect: Z = 0.79 (P = 0.43)
Test for subgroup differences: Chi2 = 0.09, df = 1 (P = 0.77), I2 =0.0%
0.01 0.1 1 10 100
Favours basic Favours foam
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Analysis 4.2. Comparison 4 Foam dressings compared with basic wound contact dressings, Outcome 2
Time to complete healing (in days), medium-term follow-up.
Review: Foam dressings for treating pressure ulcers
Comparison: 4 Foam dressings compared with basic wound contact dressings
Outcome: 2 Time to complete healing (in days), medium-term follow-up
Study or subgroup Foam dressing Basic dressings
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Souliotis 2016 47 85.6 (52.1) 48 121.4 (52.2) -35.80 [ -56.77, -14.83 ]
Test for subgroup differences: Not applicable
-100 -50 0 50 100
Favours foam Favours basic
Analysis 4.3. Comparison 4 Foam dressings compared with basic wound contact dressings, Outcome 3
Adverse events, medium-term follow-up.
Review: Foam dressings for treating pressure ulcers
Comparison: 4 Foam dressings compared with basic wound contact dressings
Outcome: 3 Adverse events, medium-term follow-up
Study or subgroup Foam dressings Basic dressings Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Souliotis 2016 12/47 21/48 0.58 [ 0.33, 1.05 ]
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours foam Favours basic
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A D D I T I O N A L T A B L E S
Table 1. International NPUAP/EPUAP/PPPIA Pressure Ulcer Classification System (2014)
Category/Stage Definition
Quoted directly from NPUAP/EPUAP/PPPIA 2014
Category/Stage I:
Nonblanchable Erythema
Intact skin with non-blanchable redness of a localized area usually over a bony
prominence. Darkly pigmented skin may not have visible blanching; its colour
may differ from the surrounding area. The area may be painful, firm, soft, warmer
or cooler as compared to adjacent tissue. Category/Stage I may be difficult to
detect in individuals with dark skin tones. May indicate “at risk” individuals (a
heralding sign of risk)
Category/Stage II:
Partial Thickness Skin Loss
Partial thickness loss of dermis presenting as a shallow open ulcer with a red pink
wound bed, without slough.May also present as an intact or open/ruptured serum
filled blister
Presents as a shiny or dry shallowulcerwithout slough or bruising.*ThisCategory/
Stage should not be used to describe skin tears, tape burns, perineal dermatitis,
maceration or excoriation
*Bruising indicates suspected deep tissue injury.
Category/Stage III:
Full Thickness Skin Loss
Full thickness tissue loss. Subcutaneous fat may be visible but bone, tendon or
muscle are not exposed. Slough may be present but does not obscure the depth
of tissue loss. May include undermining and tunnelling
The depth of a Category/Stage III pressure ulcer varies by anatomical location.
The bridge of the nose, ear, occiput and malleolus do not have subcutaneous
tissue and Category/Stage III ulcers can be shallow. In contrast, areas of significant
adiposity can develop extremely deep Category/Stage III pressure ulcers. Bone/
tendon is not visible or directly palpable
Category/Stage IV:
Full Thickness Tissue Loss
Full thickness tissue loss with exposed bone, tendon or muscle. Slough or eschar
may be present on some parts of the wound bed. Often include undermining and
tunnelling
The depth of a Category/Stage IV pressure ulcer varies by anatomical location.
The bridge of the nose, ear, occiput and malleolus do not have subcutaneous
tissue and these ulcers can be shallow. Category/Stage IV ulcers can extend into
muscle and/or supporting structures (e.g., fascia, tendon or joint capsule) making
osteomyelitis possible. Exposed bone/tendon is visible or directly palpable
Unstageable: Depth Unknown Full thickness tissue loss in which the base of the ulcer is covered by slough (yellow,
tan, grey, green or brown) and/or eschar (tan, brown or black) in the wound bed
Until enough slough and/or eschar is removed to expose the base of the wound,
the true depth, and therefore Category/Stage, cannot be determined. Stable (dry,
adherent, intact without erythema or fluctuance) eschar on the heels serves as ‘the
body’s natural (biological) cover’ and should not be removed
Suspected Deep Tissue Injury: Depth Unknown Purple or maroon localized area of discoloured intact skin or blood-filled blister
due to damage of underlying soft tissue from pressure and/or shear. The area may
be preceded by tissue that is painful, firm, mushy, boggy, warmer or cooler as
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Table 1. International NPUAP/EPUAP/PPPIA Pressure Ulcer Classification System (2014) (Continued)
compared to adjacent tissue
Deep tissue injury may be difficult to detect in individuals with dark skin tones.
Evolution may include a thin blister over a dark wound bed. The wound may
further evolve andbecome covered by thin eschar. Evolutionmay be rapid exposing
additional layers of tissue even with optimal treatment
Table 2. Comparison of pressure ulcer classification systems
NPUAP/
EPUAP/PPPIA Classification
System (2014, 2009)
NPUAP (1989) The UK Consensus (Stirling)
Classification of Pressure Sore
Severity (1994)
The Torrence Classification
System (1983)
Category/
Stage
Definition Category/
Stage
Definition Category/
Stage
Definition Category/
Stage
Definition
Quoted directly from
NPUAP/EPUAP/PPPIA 2014
Quoted directly from NPUAP
1989
Quoted directly from Reid
1994
Quoted directly from Harker
2000
Category/
Stage
I: Nonblanch-
able Erythema
Intact
skin with non-
blanch-
able redness of
a localized area
usually over a
bony promi-
nence. Darkly
pigmented
skin may
not have visi-
ble blanching;
its colour may
differ from the
surround-
ing area. The
area may be
painful, firm,
soft, warmer
or cooler as
compared
to adjacent tis-
sue. Category/
Stage I may be
difficult to de-
tect in individ-
uals
with dark skin
tones. May in-
dicate “at risk”
Stage I Non-blanch-
able erythema
of intact skin:
the heralding
lesion of skin
ulcer-
ation. Identifi-
cation of Stage
I pressure ul-
cers may be
difficult in pa-
tients with
darkly pig-
mented skin
Stage 1 Discol-
oration of in-
tact skin (light
finger pressure
applied to the
site does not
alter the dis-
colouration)
1.1 Non-
blanchable
erythema with
increased local
heat
1.2 Blue/pur-
ple/black dis-
colouration
Stage 1 Blanching hy-
peraemia: Re-
active hy-
peraemia is a
temporary di-
lation of the
cap-
illaries which
bring oxygen
to the area and
remove accu-
mulated
carbon diox-
ide and other
waste prod-
ucts. It causes
a distinct ery-
thema af-
ter pressure is
released. Light
finger pressure
is said to cause
blanching of
this erythema,
in-
dicating that
the microcir-
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Table 2. Comparison of pressure ulcer classification systems (Continued)
individuals (a
heralding sign
of risk)
culation is in-
tact
Cat-
egory/Stage II:
Partial Thick-
ness Skin Loss
Partial thick-
ness loss
of dermis
presenting
as a shallow
open ulcer
with a red
pink wound
bed, without
slough. May
also present
as an intact
or open/rup-
tured serum
filled blister.
Presents as
a shiny or
dry shallow
ulcer without
slough or
bruising.*
This Cate-
gory/Stage
should not
be used to
describe
skin tears,
tape burns,
perineal
dermatitis,
maceration or
excoriation.
*Bruising
indicates
suspected deep
tissue injury.
Stage II Partial thick-
ness skin loss
involving epi-
dermis and/or
dermis.
The ulcer is
superficial and
presents
clinically as an
abrasion, blis-
ter or shallow
crater
Stage 2 Partial
thickness skin
loss or damage
involving epi-
dermis and/or
dermis
2.1 Blister
2.2 Abrasion
2.3 Shallow
ulcer, without
undermining
of adjacent tis-
sue
2.
4 Any of these
with underly-
ing blue/pur-
ple/black dis-
colouration or
induration
Stage 2 Non-blanch-
ing hyper-
aemia: the
erythema
remains when
light pressure
is applied
indicating
a degree of
microcircu-
latory dis-
ruption and
inflammation.
Oedema
distorts and
thickens
all tissues
compressed
between the
bone and the
support sur-
face. Superfi-
cial damage
may present
as swelling,
induration,
blistering or
epidermal
ulceration,
which might
expose the
dermis
Cate-
gory/Stage III:
Full Thickness
Skin Loss
Full thickness
tissue loss.
Subcutaneous
fat may be
visible but
bone, tendon
or muscle are
not exposed.
Stage III Full thickness
skin loss in-
volving dam-
age or necro-
sis of subcu-
taneous tissue
that may ex-
tend down to,
Stage 3 Full-thickness
skin loss in-
volving dam-
age or necro-
sis of subcu-
taneous tissues
but
not extending
Stage 3 Ulceration
progresses
through the
dermis to the
junc-
tion with sub-
cutaneous tis-
sue. The ulcer
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Table 2. Comparison of pressure ulcer classification systems (Continued)
Slough may
be present
but does not
obscure the
depth of tissue
loss. May in-
clude under-
mining and
tunnelling.
The depth of
a Category/
Stage III
pressure ulcer
varies by
anatomical
location. The
bridge of the
nose, ear,
occiput and
malleolus
do not have
subcutaneous
tissue and
Category/
Stage III
ulcers can be
shallow. In
contrast, areas
of significant
adiposity can
develop ex-
tremely deep
Category/
Stage III pres-
sure ulcers.
Bone/tendon
is not visible
or directly
palpable
but not
through, un-
derlying fas-
cia. The ulcer
presents clini-
cally as a deep
crater with
or without un-
dermining of
adjacent tissue
to underlying
bone, tendon
or joint cap-
sule
3.
1Crater, with-
out under-
mining of ad-
jacent tissue
3.
2 Crater, with
undermining
of adjacent tis-
sue
3.3 Sinus, the
full extent of
which is not
certain
3.4 Full-thick-
ness skin loss
but wound
bed covered
with necrotic
tissue (hard or
leathery black/
brown
tissue or softer
yellow/cream/
grey
slough) which
masks the true
extent of tissue
damage. Un-
til debrided it
is not possi-
ble to observe
whether dam-
age ex-
tends into the
muscle or in-
volves damage
to bone
or supporting
structures
edges are dis-
tinct but it is
surrounded by
erythema and
induration. At
this stage the
damage is still
reversible
Cate-
gory/Stage IV:
Full Thickness
Tissue Loss
Full thickness
tissue loss
with exposed
bone, tendon
or muscle.
Stage IV Full thickness
skin loss with
extensive de-
struction,
Stage 4 Full-thickness
skin loss with
extensive de-
struction and
Stage 4 Ulceration ex-
tends into the
subcutaneous
fat. Small-ves-
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Table 2. Comparison of pressure ulcer classification systems (Continued)
Slough or
eschar may
be present on
some parts of
the wound
bed. Often in-
clude under-
mining and
tunnelling.
The depth of
a Category/
Stage IV
pressure ulcer
varies by
anatomical
location. The
bridge of the
nose, ear,
occiput and
malleolus
do not have
subcutaneous
tissue and
these ulcers
can be shal-
low. Cate-
gory/Stage
IV ulcers can
extend into
muscle and/
or supporting
structures
(e.g., fascia,
tendon or
joint capsule)
making os-
teomyelitis
possible. Ex-
posed bone/
tendon is visi-
ble or directly
palpable. The
depth of a
Category/
Stage IV
pressure ulcer
varies by
anatomical
tissue necrosis
or damage to
muscle, bone,
or supporting
structures (for
exam-
ple, tendon or
joint capsule)
. Note: under-
mining and si-
nus tracts may
also be associ-
ated with
Stage IV pres-
sure ulcers
tissue necrosis
extending
to underlying
bone, tendon
or joint cap-
sule
4.1 Visible ex-
po-
sure of bone,
tendon or cap-
sule
4.2 Sinus as-
sesses as ex-
tending to
bone, tendon
or capsule.
sel thrombosis
and infection
compound fat
necrosis. Un-
derlying mus-
cle is swollen
and inflamed,
and undergoes
pathological
changes. The
relative avas-
cular deep fas-
cia temporar-
ily im-
pedes down-
ward progress
of the damage
but promotes
lateral exten-
sion, causing
un-
dermining of
the skins. Epi-
dermal thick-
ening creates a
distinct ulcer
margin but in-
flam-
mation, fibro-
sis and retrac-
tion distort
the deeper ar-
eas of the sore
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Table 2. Comparison of pressure ulcer classification systems (Continued)
location. The
bridge of the
nose, ear,
occiput and
malleolus
do not have
subcutaneous
tissue and
these ulcers
can be shal-
low. Cate-
gory/Stage
IV ulcers can
extend into
muscle and/
or supporting
structures
(e.g., fascia,
tendon or
joint capsule)
making os-
teomyelitis
possible. Ex-
posed bone/
tendon is visi-
ble or directly
palpable
Unstageable:
Depth
Unknown
Full thick-
ness tissue loss
in which the
base of the ul-
cer is covered
by slough (yel-
low, tan, grey,
green or
brown) and/or
eschar
(tan, brown or
black) in the
wound bed.
Until enough
slough and/or
eschar is re-
moved to ex-
pose the base
of the wound,
the true depth,
and there-
Unstageable When eschar
is present, ac-
curate staging
of the pressure
ulcer is not
possible until
the eschar has
sloughed or
the wound has
been debrided
Stage 5 In-
fective necro-
sis penetrates
the deep fas-
cia, and mus-
cle destruction
pro-
gresses rapidly.
The wound
spreads
along the fas-
cial planes and
bursae,
and may even
reach
the joints and
body cavities.
Osteomyeli-
tis can easily
76Foam dressings for treating pressure ulcers (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 2. Comparison of pressure ulcer classification systems (Continued)
fore Category/
Stage, can-
not be deter-
mined. Stable
(dry, adherent,
intact without
ery-
thema or fluc-
tuance) eschar
on the heels
serves as ‘the
body’s natural
(biologi-
cal) cover’ and
should not be
removed
develop. Mul-
tiple
pressure ulcers
may join, re-
sulting inmas-
sive areas of
tissue destruc-
tion
Suspected
Deep Tissue
Injury: Depth
Unknown
Purple or
maroon local-
ized area of
discoloured
intact skin or
blood-filled
blister due
to damage of
underlying
soft tissue
from pressure
and/or shear.
The area may
be preceded
by tissue that
is painful,
firm, mushy,
boggy, warmer
or cooler as
compared
to adjacent
tissue. Deep
tissue injury
may be diffi-
cult to detect
in individuals
with dark skin
tones. Evo-
lution may
include a thin
blister over a
dark wound
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Table 2. Comparison of pressure ulcer classification systems (Continued)
bed. The
wound may
further evolve
and become
covered by
thin eschar.
Evolution
may be rapid
exposing ad-
ditional layers
of tissue even
with optimal
treatment
Table 3. Summary of outcomes
Study Inter-
vention
Com-
parator
Fol-
low-up
(weeks)
Inci-
dence
of
healed
PU
Time
to com-
plete
healing
Ad-
verse
events
Reduc-
tion
in ulcer
size
Qual-
ity of
life
Patient
satis-
faction
PU re-
cur-
rence
Pain Eco-
nomic
Bale
1997 Polyurethane
foam (n
= 29)
Hydro-
colloid
(n = 31)
4
√ × √ × × × × × ×
Bale
1998
Hydro-
cellular
foam (n
= 17)
Hydro-
colloid
(n = 15)
8 × × √ Data
not sep-
a-
rated by
wound
type
√
Data
not sep-
a-
rated by
wound
type
× √ × × √
Banks
1994a Polyurethane
foam (n
= 26)
Knit-
ted vis-
cous se-
cured
with a
vapour-
perme-
able
film
dress-
ing (n =
24)
12
√ × × × × √ × √ ×
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Table 3. Summary of outcomes (Continued)
Meaume
2003
Silicone
polyurethane
foam (n
= 18)
Hy-
dropoly-
mer
foam (n
= 20)
8
√ × √ √ × × × × ×
Payne
2009 Polyurethane
foam (n
= 20)
Saline-
soaked
gauze
(n = 16)
4
√ × × √ × × × × √
Seeley
1999
Hydro-
cellular
foam (n
= 20)
Hydro-
colloid
(n = 19)
8
√ × √ × × × × √ ×
Sopata
2002 Polyurethane
foam (n
= 17)
Hydro-
gel (n =
17)
8
√ √ √ √ × × × × ×
Soulio-
tis
2016
Foam
dress-
ings,
foam
with sil-
ver, sil-
ver-
sulfadi-
azine
and
ibupro-
fen (n =
47)
Plain
and
saline-
soaked
gauze
(n = 48)
Un-
til com-
plete
heal-
ing (less
than 24
weeks)
× √ √ × × × × × √
Thomas
1997
Hy-
dropoly-
mer (n
= 50)
Hydro-
colloid
(n = 49)
6
√ × √ √ Data
not sep-
a-
rated by
wound
type
× × × √ ×
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A P P E N D I C E S
Appendix 1. Search strategies
Cochrane Wounds Specialised Register
1 MESH DESCRIPTOR Pressure Ulcer EXPLODE ALL AND INREGISTER
2 (pressure next (ulcer* or sore* or injur*)) AND INREGISTER
3 (decubitus next (ulcer* or sore*)) AND INREGISTER
4 ((bed next sore*) or bedsore) AND INREGISTER
5 #1 OR #2 OR #3 OR #4
6 MESH DESCRIPTOR Bandages EXPLODE ALL AND INREGISTER
7 MESH DESCRIPTOR Polyurethanes EXPLODE ALL AND INREGISTER
8 MESH DESCRIPTOR Silicones EXPLODE ALL AND INREGISTER
9 foam* AND INREGISTER
10 polyurethane* AND INREGISTER
11 silicone* AND INREGISTER
12 hydrocellular or hydropolymer* AND INREGISTER
13 ActivHeal or Allevyn or Advazorb or Biatain or Copa or LyoFoam or PermaFoam or PolyMem or Suprasorb or Tegaderm or Tielle
or Transorbent or Trufoam or UrgoCell or Cutimed or Kendall or Askina or Kerraboot or Cavi-care or Mepilex AND INREGISTER
14 #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13
15 #5 AND #14
The Cochrane Central Register of Controlled Clinical Trials (CENTRAL)
#1 MeSH descriptor: [Pressure Ulcer] explode all trees
#2 (pressure next (ulcer* or sore* or injur*)):ti,ab,kw
#3 (decubitus next (ulcer* or sore*)):ti,ab,kw
#4 ((bed next sore*) or bedsore):ti,ab,kw
#5 #1 or #2 or #3 or #4
#6 MeSH descriptor: [Bandages] explode all trees
#7 MeSH descriptor: [Polyurethanes] explode all trees
#8 MeSH descriptor: [Silicones] explode all trees
#9 (foam*):ti,ab,kw
#10 (polyurethane*):ti,kw,ab
#11 (silicone*):ti,kw,ab
#12 (hydrocellular or hydropolymer*):ti,kw,ab
#13 (ActivHeal or Allevyn or Advazorb or Biatain or Copa or LyoFoam or PermaFoam or PolyMem or Suprasorb or Tegaderm or Tielle
or Transorbent or Trufoam or UrgoCell or Cutimed or Kendall or Askina or Kerraboot or Cavi-care or Mepilex):ti,kw,ab
#14 #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13
#15 #5 and #14
The NHS Economic Evaluation Database (NHS EED)
#1 MeSH descriptor: [Pressure Ulcer] explode all trees
#2 (pressure next (ulcer* or sore* or injur*)):ti,ab,kw
#3 (decubitus next (ulcer* or sore*)):ti,ab,kw
#4 ((bed next sore*) or bedsore):ti,ab,kw
#5 #1 or #2 or #3 or #4
#6 MeSH descriptor: [Bandages] explode all trees
#7 MeSH descriptor: [Polyurethanes] explode all trees
#8 MeSH descriptor: [Silicones] explode all trees
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#9 (foam*):ti,ab,kw
#10 (polyurethane*):ti,kw,ab
#11 (silicone*):ti,kw,ab
#12 (hydrocellular or hydropolymer*):ti,kw,ab
#13 (ActivHeal or Allevyn or Advazorb or Biatain or Copa or LyoFoam or PermaFoam or PolyMem or Suprasorb or Tegaderm or Tielle
or Transorbent or Trufoam or UrgoCell or Cutimed or Kendall or Askina or Kerraboot or Cavi-care or Mepilex):ti,kw,ab
#14 #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13
#15 #5 and #14
Ovid MEDLINE
1 exp Pressure Ulcer/
2 (pressure adj (ulcer* or sore* or injur*)).ab,kw,ti.
3 (decubitus adj (ulcer* or sore*)).ab,kw,ti.
4 (bed next sore* or bedsore).ab,kw,ti.
5 or/1-4
6 exp Bandages/
7 Polyurethanes/
8 exp Silicones/
9 foam*.ab,kw,ti.
10 polyurethane*.ab,kw,ti.
11 silicone*.ab,kw,ti.
12 (hydrocellular or hydropolymer*).ab,kw,ti.
13 (ActivHeal or Allevyn or Advazorb or Biatain or Copa or LyoFoam or PermaFoam or PolyMem or Suprasorb or Tegaderm or Tielle
or Transorbent or Trufoam or UrgoCell or Cutimed or Kendall or Askina or Kerraboot or Cavi-care or Mepilex).ab,kw,ti.
14 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13
15 5 and 14
16 randomized controlled trial.pt.
17 controlled clinical trial.pt.
18 randomi?ed.ab.
19 placebo.ab.
20 clinical trials as topic.sh.
21 randomly.ab.
22 trial.ti.
23 or/16-22
24 exp animals/ not humans.sh.
25 23 not 24
26 15 and 25
Search for economic studies in Ovid MEDLINE:
1 exp Pressure Ulcer/
2 (pressure adj (ulcer* or sore* or injur*)).ab,kw,ti.
3 (decubitus adj (ulcer* or sore*)).ab,kw,ti.
4 (bed next sore* or bedsore).ab,kw,ti.
5 or/1-4
6 exp Bandages/
7 Polyurethanes/
8 exp Silicones/
9 foam*.ab,kw,ti.
10 polyurethane*.ab,kw,ti.
11 silicone*.ab,kw,ti.
12 (hydrocellular or hydropolymer*).ab,kw,ti.
13 (ActivHeal or Allevyn or Advazorb or Biatain or Copa or LyoFoam or PermaFoam or PolyMem or Suprasorb or Tegaderm or Tielle
or Transorbent or Trufoam or UrgoCell or Cutimed or Kendall or Askina or Kerraboot or Cavi-care or Mepilex).ab,kw,ti.
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14 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13
15 5 and 14
16 economics/
17 exp “costs and cost analysis”/
18 economics, dental/
19 exp “economics, hospital”/
20 economics, medical/
21 economics, nursing/
22 economics, pharmaceutical/
23 (economic* or cost or costs or costly or costing or price or prices or pricing or pharmacoeconomic*).ti,ab.
24 (expenditure* not energy).ti,ab.
25 value for money.ti,ab.
26 budget*.ti,ab.
27 or/16-26
28 ((energy or oxygen) adj cost).ti,ab.
29 (metabolic adj cost).ti,ab.
30 ((energy or oxygen) adj expenditure).ti,ab.
31 or/28-30
32 27 not 31
33 letter.pt.
34 editorial.pt.
35 historical article.pt.
36 or/33-35
37 32 not 36
38 exp Animals/ not humans/
39 37 not 38
40 15 and 39
Ovid Embase
1 exp decubitus/
2 (pressure adj (ulcer* or sore* or injur*)).ti,kw,ab.
3 (decubitus adj (ulcer* or sore*)).ti,kw,ab.
4 (bed next sore* or bedsore).ti,kw,ab.
5 or/1-4
6 exp foam dressing/
7 exp polyurethan/
8 exp silicone derivative/
9 foam*.ti,kw,ab.
10 polyurethan*.ti,kw,ab.
11 silicone*.ti,kw,ab.
12 (hydrocellular or hydropolymer*).ab,kw,ti.
13 (ActivHeal or Allevyn or Advazorb or Biatain or Copa or LyoFoam or PermaFoam or PolyMem or Suprasorb or Tegaderm or Tielle
or Transorbent or Trufoam or UrgoCell or Cutimed or Kendall or Askina or Kerraboot or Cavi-care or Mepilex).ti,kw,ab.
14 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13
15 5 and 14
16 Randomized controlled trials/
17 Single-Blind Method/
18 Double-Blind Method/
19 Crossover Procedure/
20 (random* or factorial* or crossover* or cross over* or cross-over* or placebo* or assign* or allocat* or volunteer*).ti,ab.
21 (doubl* adj blind*).ti,ab.
22 (singl* adj blind*).ti,ab.
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23 or/16-22
24 exp animals/ or exp invertebrate/ or animal experiment/ or animal model/ or animal tissue/ or animal cell/ or nonhuman/
25 human/ or human cell/
26 and/24-25
27 24 not 26
28 23 not 27
29 15 and 28
Search for economic studies in Ovid Embase:
1 exp decubitus/
2 (pressure adj (ulcer* or sore* or injur*)).ti,kw,ab.
3 (decubitus adj (ulcer* or sore*)).ti,kw,ab.
4 (bed next sore* or bedsore).ti,kw,ab.
5 or/1-4
6 exp foam dressing/
7 exp polyurethan/
8 exp silicone derivative/
9 foam*.ti,kw,ab.
10 polyurethan*.ti,kw,ab.
11 silicone*.ti,kw,ab.
12 (hydrocellular or hydropolymer*).ab,kw,ti.
13 (ActivHeal or Allevyn or Advazorb or Biatain or Copa or LyoFoam or PermaFoam or PolyMem or Suprasorb or Tegaderm or Tielle
or Transorbent or Trufoam or UrgoCell or Cutimed or Kendall or Askina or Kerraboot or Cavi-care or Mepilex).ti,kw,ab.
14 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13
15 5 and 14
16 health-economics/
17 exp economic-evaluation/
18 exp health-care-cost/
19 exp pharmacoeconomics/
20 or/16-19
21 (econom* or cost or costs or costly or costing or price or prices or pricing or pharmacoeconomic*).ti,ab.
22 (expenditure* not energy).ti,ab.
23 (value adj2 money).ti,ab.
24 budget*.ti,ab.
25 or/21-24
26 20 or 25
27 letter.pt.
28 editorial.pt.
29 note.pt.
30 or/27-29
31 26 not 30
32 (metabolic adj cost).ti,ab.
33 ((energy or oxygen) adj cost).ti,ab.
34 ((energy or oxygen) adj expenditure).ti,ab.
35 or/32-34
36 31 not 35
37 exp animal/
38 exp animal-experiment/
39 nonhuman/
40 (rat or rats or mouse or mice or hamster or hamsters or animal or animals or dog or dogs or cat or cats or bovine or sheep).ti,ab,sh.
41 or/37-40
42 exp human/
43 exp human-experiment/
44 or/42-43
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45 41 not (41 and 44)
46 36 not 45
47 15 and 46
EBSCO CINAHL Plus
S29 S15 AND S28
S28 S16 OR S17 OR S18 OR S19 OR S20 OR S21 OR S22 OR S23 OR S24 OR S25 OR S26 OR S27
S27 TI allocat* random* or AB allocat* random*
S26 MH “Quantitative Studies”
S25 TI placebo* or AB placebo*
S24 MH “Placebos”
S23 TI random* allocat* or AB random* allocat*
S22 MH “Random Assignment”
S21 TI randomi?ed control* trial* or AB randomi?ed control* trial*
S20 AB ( singl* or doubl* or trebl* or tripl* ) and AB ( blind* or mask* )
S19 TI ( singl* or doubl* or trebl* or tripl* ) and TI ( blind* or mask* )
S18 TI clinic* N1 trial* or AB clinic* N1 trial*
S17 PT Clinical trial
S16 MH “Clinical Trials+”
S15 S5 AND S14
S14 S6 OR S7 OR S8 OR S9 OR S10 OR S11 OR S12 OR S13
S13 TI ( ActivHeal or Allevyn or Advazorb or Biatain or Copa or LyoFoam or PermaFoam or PolyMem or Suprasorb or Tegaderm
or Tielle or Transorbent or Trufoam or UrgoCell or Cutimed or Kendall or Askina or Kerraboot or Cavi-care or Mepilex ) OR AB (
ActivHeal or Allevyn or Advazorb or Biatain or Copa or LyoFoam or PermaFoam or PolyMem or Suprasorb or Tegaderm or Tielle or
Transorbent or Trufoam or UrgoCell or Cutimed or Kendall or Askina or Kerraboot or Cavi-care or Mepilex )
S12 TI ( hydrocellular or hydropolymer* ) OR AB ( hydrocellular or hydropolymer* )
S11 TI silicone* OR AB silicone*
S10 TI polyurethan* OR AB polyurethan*
S9 TI foam* OR AB foam*
S8 (MH “Silicones+”)
S7 (MH “Polyurethanes”)
S6 (MH “Foam Dressings”)
S5 S1 OR S2 OR S3 OR S4
S4 TI decubitus or AB decubitus
S3 TI ( bed sore* or bedsore* ) or AB ( bed sore* or bedsore* )
S2 TI ( pressure ulcer* or pressure sore* ) or AB ( pressure ulcer* or pressure sore* )
S1 (MH “Pressure Ulcer+”)
Search for economic studies in EBSCO CINAHL Plus:
S38 S15 AND S37
S37 S33 NOT S36
S36 S19 NOT (S19 AND S35)
S35 MH “Human”
S34 MH “Animal Studies”
S33 S28 NOT S32
S32 S29 or S30 or S31
S31 PT commentary
S30 PT letter
S29 PT editorial
S28 S26 OR S27
S27 TI (cost or costs or economic* or pharmacoeconomic* or price* or pricing*) OR AB (cost or costs or economic* or pharmacoeco-
nomic* or price* or pricing*)
S26 S22 OR S25
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S25 S23 OR S24
S24 MH “Health Resource Utilization”
S23 MH “Health Resource Allocation”
S22 S16 NOT S21
S21 S17 OR S18 or S19 OR S20
S20 MH “Business+”
S19 MH “Financing, Organized+”
S18 MH “Financial Support+”
S17 MH “Financial Management+”
S16 MH “Economics+”
S15 S5 AND S14
S14 S6 OR S7 OR S8 OR S9 OR S10 OR S11 OR S12 OR S13
S13 TI ( ActivHeal or Allevyn or Advazorb or Biatain or Copa or LyoFoam or PermaFoam or PolyMem or Suprasorb or Tegaderm
or Tielle or Transorbent or Trufoam or UrgoCell or Cutimed or Kendall or Askina or Kerraboot or Cavi-care or Mepilex ) OR AB (
ActivHeal or Allevyn or Advazorb or Biatain or Copa or LyoFoam or PermaFoam or PolyMem or Suprasorb or Tegaderm or Tielle or
Transorbent or Trufoam or UrgoCell or Cutimed or Kendall or Askina or Kerraboot or Cavi-care or Mepilex )
S12 TI ( hydrocellular or hydropolymer* ) OR AB ( hydrocellular or hydropolymer* )
S11 TI silicone* OR AB silicone*
S10 TI polyurethan* OR AB polyurethan*
S9 TI foam* OR AB foam*
S8 (MH “Silicones+”)
S7 (MH “Polyurethanes”)
S6 (MH “Foam Dressings”)
S5 S1 OR S2 OR S3 OR S4
S4 TI decubitus or AB decubitus
S3 TI ( bed sore* or bedsore* ) or AB ( bed sore* or bedsore* )
S2 TI ( pressure ulcer* or pressure sore* ) or AB ( pressure ulcer* or pressure sore* )
S1 (MH “Pressure Ulcer+”)
ClinicalTrials.gov
Foam dressing OR bandage AND pressure ulcer treatment
Foam dressing OR bandage AND bed sore treatment
Foam dressing OR bandage AND decubitis ulcer treatment
World Health Organization International Clinical Trials Registry Platform
Foam dressing OR bandage AND pressure ulcer treatment
Foam dressing OR bandages OR polyurethanes OR silicones AND pressure ulcer OR pressure injury OR bed sore OR decubitis ulcer
AND treatment
Foam dressing OR bandage AND pressure ulcer OR pressure injury OR bed sore OR decubitis ulcer AND treatment
EU Clinical Trials Register
Foam dressing OR bandage AND pressure ulcer OR pressure injury OR bed sore OR decubitis ulcer AND treatment
Appendix 2. Assessment of risk of bias criteria
1. Was the allocation sequence randomly generated?
Low risk of bias
The investigators describe a random component in the sequence generation process such as: referring to a random number table; using
a computer random number generator; coin tossing; shuffling cards or envelopes; throwing dice; drawing of lots.
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High risk of bias
The investigators describe a non-random component in the sequence-generation process. Usually, the description would involve some
systematic, non-random approach, for example: sequence generated by odd or even date of birth; sequence generated by some rule
based on date (or day) of admission; sequence generated by some rule based on hospital or clinic record number.
Unclear
Insufficient information about the sequence generation process to permit judgement of low or high risk of bias.
2. Was the treatment allocation adequately concealed?
Low risk of bias
Participants and investigators enrolling participants could not foresee assignment because one of the following, or an equivalent
method, was used to conceal allocation: central allocation (including telephone, web-based and pharmacy-controlled randomisation);
sequentially numbered drug containers of identical appearance; sequentially numbered, opaque, sealed envelopes.
High risk of bias
Participants or investigators enrolling participants could possibly foresee assignments and thus introduce selection bias, such as allocation
based on: use of an open, random allocation schedule (e.g. a list of random numbers); assignment envelopes without appropriate
safeguards (e.g. envelopes were unsealed, non-opaque or not sequentially numbered); alternation or rotation; date of birth; case record
number; any other explicitly unconcealed procedure.
Unclear
Insufficient information to permit judgement of low or high risk of bias. This is usually the case if the method of concealment is not
described or not described in sufficient detail to allow a definite judgement, for example if the use of assignment envelopes is described,
but it remains unclear whether envelopes were sequentially numbered, opaque and sealed.
3. Blinding - was knowledge of the allocated interventions adequately prevented during the study?
Low risk of bias
Any one of the following.
• No blinding, but the review authors judge that the outcome and the outcome measurement are not likely to be influenced by
lack of blinding.
• Blinding of participants and key study personnel ensured, and unlikely that the blinding could have been broken.
• Either participants or some key study personnel were not blinded, but outcome assessment was blinded and the non-blinding of
others was unlikely to introduce bias.
High risk of bias
Any one of the following.
• No blinding or incomplete blinding, and the outcome or outcome measurement is likely to be influenced by lack of blinding.
• Blinding of key study participants and personnel attempted, but likely that the blinding could have been broken.
• Either participants or some key study personnel were not blinded, and the non-blinding of others was likely to introduce bias.
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Unclear
Either of the following.
• Insufficient information to permit judgement of low or high risk of bias.
• The study did not address this outcome.
4. Were incomplete outcome data adequately addressed?
Low risk of bias
Any one of the following.
• No missing outcome data.
• Reasons for missing outcome data unlikely to be related to true outcome (for survival data, censoring unlikely to be introducing
bias).
• Missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups.
• For dichotomous outcome data, the proportion of missing outcomes compared with observed event risk not enough to have a
clinically relevant impact on the intervention effect estimate.
• For continuous outcome data, plausible effect size (difference in means or standardised difference in means) among missing
outcomes not enough to have a clinically relevant impact on observed effect size.
• Missing data have been imputed using appropriate methods.
High risk of bias
Any one of the following:
• Reason for missing outcome data likely to be related to true outcome, with either imbalance in numbers or reasons for missing
data across intervention groups.
• For dichotomous outcome data, the proportion of missing outcomes compared with observed event risk enough to induce
clinically relevant bias in intervention effect estimate.
• For continuous outcome data, plausible effect size (difference in means or standardised difference in means) among missing
outcomes enough to induce clinically relevant bias in observed effect size.
• ’As-treated’ analysis done with substantial departure of the intervention received from that assigned at randomisation.
• Potentially inappropriate application of simple imputation.
Unclear
Either of the following:
• Insufficient reporting of attrition/exclusions to permit judgement of low or high risk of bias (e.g. number randomised not stated,
no reasons for missing data provided).
• The study did not address this outcome.
5. Are reports of the study free of suggestion of selective outcome reporting?
Low risk of bias
Either of the following.
• The study protocol is available and all of the study’s pre-specified (primary and secondary) outcomes that are of interest in the
review have been reported in the pre-specified way.
• The study protocol is not available but it is clear that the published reports include all expected outcomes, including those that
were pre-specified (convincing text of this nature may be uncommon).
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High risk of bias
Any one of the following.
• Not all of the study’s pre-specified primary outcomes were reported.
• One or more primary outcomes were reported using measurements, analysis methods or subsets of the data (e.g. subscales) that
had not been pre-specified.
• One or more reported primary outcomes had not been pre-specified (unless clear justification for their reporting was provided,
such as an unexpected adverse effect).
• One or more outcomes of interest in the review were reported incompletely so that they could not be entered in a meta-analysis.
• The study report failed to include results for a key outcome that would be expected to have been reported for such a study.
Unclear
Insufficient information to permit judgement of low or high risk of bias. It is likely that the majority of studies will fall into this category.
6. Other sources of potential bias
Low risk of bias
The study appears to be free of other sources of bias.
High risk of bias
There is at least one important risk of bias. For example, the study:
• had a potential source of bias related to the specific study design used; or
• had extreme baseline imbalance; or
• has been claimed to have been fraudulent; or
• had some other problem.
Unclear
There may be a risk of bias, but there is either:
• insufficient information to assess whether an important risk of bias exists; or
• insufficient rationale or evidence that an identified problem will introduce bias.
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Alternative pressure ulcer classification systems
The main difference between the protocol and the review is the description for assessing a Category/Stage I and II pressure ulcer.
The published protocol for the section titled ’Types of participants’ described the following inclusion and exclusion criteria:
“People of any age with an existing pressure ulcer of Category/Stage II or above in any care settings. Studies including people with
only Category/Stage I pressure ulcers are excluded, as, although ’at-risk’ signs and symptoms of potential pressure ulcer such as non-
blanchable redness, pain, hardness or softness, heat or coolness are present, the skin remains intact AWMA 2012.”
A posteriori uncertainty about what constituted a Category/Stage I and II pressure ulcer in alternative pressure ulcer classification
systems led to the current review being changed. This was because the initial working definition was based upon the then Australian
Wound Management Association and Pan Pacific Partners ’Pan Pacific Clinical Practice Guideline for the Prevention and Management
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of Pressure Injury’. At the time of writing the protocol it was a draft document for consultation. The accepted system of grading now
more closely resembles other internationally accepted pressure ulcer grading systems.
In this review, as reported in ’Types of participants’, we accepted study authors’ alternative pressure ulcer classification systems, such as
the Stirling (Reid 1994) and Torrence classification systems (Harker 2000), as well as earlier versions published by the NPUAP (NPUAP
1989), on the condition that the definitions of these alternative and previous versions closely matched the contemporary International
NPUAP/EPUAP/PPPIA Pressure Ulcer Classification System Criteria (NPUAP/EPUAP/PPPIA 2014). See Table 2 ’Comparisons of
pressure ulcer classification systems’.
We also included studies that recruited participants with Category/Stage II pressure ulcers or above alongside with people with other
types of chronic wounds, such as venous and arterial leg ulcers or diabetic foot ulcers, if the results for people with relevant pressure
ulcers were presented separately (or this data were available from study authors). Similarly when a study included both Category/Stage
I and more advanced pressure ulcers, we included it in the review only if data for Category/Stage II and above were reported separately
or if the data were available on request from study authors. We also included studies where pressure ulcers from Category/Stage II and
above were reported collectively.
Follow-up periods
The included studies presented analyses for primary and secondary outcomes based on different time points. For clarity and consistency,
we have presented the pooled analyses relative to short-term follow-up (8 weeks or less); medium follow-up (24 weeks or less) and long-
term follow-up (more than 24 weeks).
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